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ABSTRACT 
Background  Hydrophobic steroid hormone derivatives, exclusively carried in 
plasma by lipoprotein particles, constitute a unique hormone family. These steroid 
fatty acyl esters are reportedly enriched in adipose tissue, which has the enzyme 
machinery necessary for the synthesis of estrogen from precursor steroids. This is of 
potential importance in postmenopausal women whose ovaries have ceased to 
secrete estrogens into the circulation. However, these hormonally inactive steroid 
fatty acyl esters, such as 17?-estradiol (E2) fatty acyl esters and 
dehydroepiandrosterone (DHEA) fatty acyl esters, need to be liberated from their 
fatty acyl partner before their relevant metabolic functions can occur. The aims are 
to explore the enzymes involved in the hydrolysis of steroid fatty acyl esters in target 
tissues and to quantify DHEA and E2 fatty acyl esters at various sites in adipose 
tissue and serum both in men and women.    
Methods  The incorporation of low-density lipoprotein (LDL)-associated 
[3H]DHEA fatty acyl esters into cultured HeLa cells was determined by radioactivity 
counting, and production of free [3H]steroids was analyzed by hydrophobic 
chromatography and one- or two-dimensional thin layer chromatography (TLC). 
Lysosomal acid lipase (LAL) was depleted from HeLa cells by use of small 
interfering RNAs. The hydrolysis of [3H]DHEA fatty acyl esters in LAL-depleted 
HeLa cells and Wolman fibroblasts was monitored by TLC. In addition, the amounts 
of DHEA fatty acyl esters in women’s adipose tissue and serum were quantified by 
gas chromatography–mass spectrometry (GC–MS) or liquid chromatography–
tandem mass spectrometry (LC–MS/MS). E2 fatty acyl ester concentrations in 
human adipose tissue and serum were quantified by time-resolved 
fluoroimmunoassay (TR-FIA), a part of which was confirmed by LC–MS/MS. The 
fatty acyl esterifying activity was accessed by incubation [3H]steroids with adipose 
tissue microsomal fraction, and esterase activity was by incubation [3H]steroid 
esters with tissue homogenates. The mRNA levels of estrogen-regulating enzymes in 
adipose tissue in obese men and women were analyzed by quantitative real-time 
PCR. 
Results  The amounts of cellular [3H]radioactivity increased with increasing 
incubation time, and could be inhibited up to ~90% by excess unlabeled LDL. 
During 48 h of chase, intracellular [3H]DHEA fatty acyl esters decreased, while at 
the same time, in the medium, rising amounts appeared of unesterified [3H]DHEA 
and its two metabolites: [3H]-5?-androstanedione (5?-adione) and 
[3H]androstenedione (4-adione). Compared to [3H]cholesteryl esters, depletion of 
LAL from HeLa cells had a more modest but significantly reducing effect on the 
hydrolysis of [3H]DHEA fatty acyl esters. Moreover, experiments in LAL-deficient 
human fibroblasts showed that [3H]DHEA fatty acyl ester hydrolysis was not 
completely dependent on LAL activity.  
No detectable amounts of DHEA fatty acyl esters were apparent in adipose tissue 
although 32–178 pmol/g of free DHEA was quantified by GC–MS and LC–MS/MS 
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analyses. By GC-MS analysis, the median concentration of DHEA fatty acyl esters in 
serum was 1.2 pmol/ml in premenopause (n=7), and 0.6 pmol/ml in 
postmenopause (n=5), respectively. The proportion of DHEA fatty acyl esters of 
total DHEA (DHEA fatty acyl esters + free DHEA) in serum was 7.4 % (median) in 
pre- and 11.2% in postmenopause, respectively. When analyzed by LC–MS/MS, 
DHEA fatty acyl ester concentrations in serum were below the assay detection limit 
(signal-to-noise ratio, S/N=10), whereas the DHEA levels in serum and adipose 
tissue were comparable and significantly correlated with those obtained by GC-MS.   
Compared to esters of [3H]DHEA and [3H]cholesterol, the hydrolysis of [3H]E2 
esters in human breast adipose tissue was much slower, whereas the esterification 
rate of [3H]E2 was higher. The hydrolysis of [3H]E2 esters in adipose tissue was 
reduced by 33–51% by inhibition of HSL.  
In breast subcutaneous adipose tissue, the median concentration of E2 fatty acyl 
esters was 987 fmol/g in pre- (n=8) and 1056 fmol/g in postmenopause (n=4), 
respectively. It was comparable to or higher than free E2. In obese men (n=14), E2 
fatty acyl ester concentrations in subcutaneous abdominal adipose tissue (251 
fmol/g, median concentration) were similar to those of E2 (262 fmol/g), but in obese 
women (n=22) were significantly lower than for E2 (255 vs. 422 fmol/g). The results 
from visceral adipose tissue were similar. In obese subjects, E2 fatty acyl esters levels 
in adipose tissue significantly correlated with serum levels, but E2 did not. 
Compared to obese men, E2 levels in subcutaneous adipose tissue in obese women 
were higher, along with higher relative mRNA expression of steroid sulfatase and 
17ß-hydroxysteroid dehydrogenases (HSD) 1, 7, and 12.  
Conclusions  LDL-associated [3H]DHEA fatty acyl esters may partially be 
taken up in cultured HeLa cells via LDL receptor or LDL receptor-related receptors 
such as LDL receptor-related protein 1 (LRP1). After intracellular hydrolysis, 
biologically active free [3H]DHEA was further metabolized to [3H]5?-adione and 
[3H]4-adione, which were secreted by the cells. Lysosomal acid lipase partially 
contributed to the hydrolysis of [3H]DHEA fatty acyl esters. Secondly, while 
relatively high concentrations of free DHEA occurred, no detectable amounts of 
DHEA fatty acyl esters in human adipose tissue were measured by either GC–MS- or 
LC–MS/MS analyses. DHEA fatty acyl ester concentrations in serum were 0.5–2.8 
pmol/ml as determined by GC–MS analysis, and the proportion of DHEA fatty acyl 
esters to the total DHEA in serum was approximately 9%. Third, subcutaneous 
adipose tissue from the human breast had E2 fatty acyl esterifying and hydrolyzing 
activity, and the hydrolysis process was partly dependent on HSL. Last, the 
production of E2 from a large adipose mass was not reflected by increased 
circulating E2 concentrations in severely obese men or women. However, adipose 
tissue may contribute to serum E2 fatty acyl ester concentrations. 
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1 INTRODUCTION 
Steroid fatty acyl esters such as 17?-estradiol (E2) fatty acyl esters and 
dehydroepiandrosterone (DHEA) fatty acyl esters belong to a unique family of naturally 
occurring hydrophobic hormone derivatives (Hochberg 1998, Vihma & Tikkanen 2011). 
These steroids are esterified in a reaction catalyzed by lecithin-cholesterol 
acyltransferase (LCAT) associated with high-density lipoprotein (HDL) particles and 
are transported to other lipoprotein particles (Pahuja & Hochberg 1995, Provost et al. 
1997, Kanji et al. 1999, Helisten et al. 2001, Höckerstedt et al. 2002). The physiological 
role of steroid fatty acyl esters remains unclear. E2 fatty acyl esters have been 
considered as the storage form of active estrogen in adipose tissue and may be released 
as an active unconjugated hormone (Hochberg 1998). In vitro, E2 fatty acyl esters may 
act as an antioxidant protecting lipoproteins against oxidation (Shwaery et al. 1997, 
1998). In addition, lipoprotein-associated pregnenolone fatty acyl esters and DHEA 
fatty acyl esters may serve as substrates for steroid synthesis after their entry into target 
cells (Provencher et al. 1992, Roy & Bélanger 1992). Recently, Paatela et al. (2009) have 
reported that HDL-associated DHEA fatty acyl esters may enhance the vasodilation 
effects of HDL on rat mesenteric arteries in vitro.  
Compared with E2 fatty acyl esters that are present in picomolar concentrations in 
the blood (Vihma et al. 2001, 2003a, 2004), nanomolar concentrations of circulating 
DHEA fatty acyl esters also occur (Bélanger et al. 1994, Labrie et al. 1997b, Couillard et 
al. 2000), most of which are recovered in lipoproteins (Roy & Bélanger 1989a). The 
concentrations of DHEA fatty acyl esters in adrenal tissue (Bélanger et al. 1990) and 
brain (Liere et al. 2004) have been measured by immunoassay, but no data are 
available as to whether DHEA fatty acyl esters–similar to E2 fatty acyl esters–are stored 
in the adipose tissue. Some studies indicate uptake of DHEA fatty acyl esters by 
peripheral tissues when insulin is administered to men (Lavallée et al. 1997, Nestler & 
Kahwash 1994). Lysosomal acid lipase (LAL) is involved in the intracellular hydrolysis 
of low-density lipoprotein (LDL)-associated cholesteryl esters that are taken up by 
LDL-receptor-mediated endocytosis (Goldstein et al. 1975, 1983). DHEA has a ring 
structure similar to that of cholesterol, but whether LAL plays any role in the hydrolysis 
of DHEA fatty acyl esters remains unknown. 
Adipose tissue is an active site of estrogen synthesis, a fact that is quantitatively 
important for obese subjects, as well as for postmenopausal women and men. 
Formation in adipose tissue of E2, the most potent estrogen, is an interesting biological 
issue. This process involves at least three pathways: First, after formation by aromatase 
from androstenedione (4-dione) and other androgens (Forney et al. 1981), estrone (E1) 
is converted to E2 by the enzymes of 17?-hydroxysteroid dehydrogenases (HSD) types 1, 
7, and 12 (Bellemare et al. 2009, Marchais-Oberwinkler et al. 2011). Currently, which of 
these enzymes is the most important in the reduction of E1 to E2 in human adipose 
tissue also remains unknown. Second, E2 is formed by peripheral aromatization of 
testosterone. Third, E2 is produced by the hydrolysis of E2 fatty acyl esters, which are 
the lipophilic E2 derivatives and may be accumulated in adipose tissue by means of 
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some unknown enzyme. In postmenopausal women, the formation of E1 by 
aromatization of androgen is positively correlated with body weight (Edman & 
MacDonald 1978). In men, both obesity and an increased body mass index (BMI) are 
reported to relate to the increased concentrations of E2 and E1 in their serum 
(Schneider et al. 1979, Zumoff et al. 1981). Studies on estrogen concentration in human 
subcutaneous and visceral adipose tissue are, however, scarce. In addition, fatty acyl 
esterification of E2 in the surrounding fat of the mammary gland that is an important 
estrogen target tissue has never been characterized previously. E2 fatty acyl esters do 
not bind to the estrogen receptors but need prior hydrolysis to become the free 
hormone (Janocko et al. 1984). The esterase activities are very important in regulating 
the availablity of active E2. An earlier study carried out in bovine placenta and adipose 
tissue has suggested that the hydrolyzing enzyme might be hormone-senstive lipase 
(HSL) (Lee et al. 1988), principally involved in the adipocyte triglyceride hydrolysis. 
HSL has broad substrate specificity, which is expressed in adipose tissue, as well as in 
steroidogenic tissues such as the adrenal gland and ovary (Kraemer & Shen 2002). 
The aim of the present study was to explore the metabolic cascade of LDL-
associated [3H]DHEA fatty acyl esters in cultured HeLa cells and the role of LAL in the 
hydrolysis of [3H]DHEA fatty acyl esters. Another aim was to set up a gas 
chromatography–mass spectrometry (GC–MS)- or liquid chromatography–tandam 
mass spectromerty (LC–MS/MS)-based quantified method to measure DHEA fatty acyl 
ester concentrations in adipose tissue and serum. Furthermore, we studied the 
esterification and hydrolysis of E2 fatty acyl esters in human breast subcutaneous 
adipose tissue and specifically, the role of HSL in steroid-ester hydrolysis; we also 
quantified the concentrations of E2 and E2 fatty acyl esters, and gene expression of 
estrogen-regulating enzymes in adipose tissues in obese men and women. The TR-FIA-
based quantitative method for measuring E2 fatty acyl esters was also compared by LC–
MS/MS analysis. 
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2 REVIEW OF THE LITERATURE 
2.1 Estrogen synthesis 
The biosynthesis of estrogen between pre- and postmenopausal women differs. In 
premenopausal women, the ovaries and the placenta during pregnancy are the 
principle sites for estrogen synthesis. Ovaries secrete E1 and E2, which are the most 
abundant estrogen in non-pregnant premenopausal women. During pregnancy, the 
placenta synthesizes a large amount of E1 and estriol (E3), which become the major 
estrogen in circulation. After menopause, however, the ovaries cease to secrete estrogen 
into the circulation. Thus, in postmenopausal women as well as in elderly men, the 
major estrogen is formed in peripheral tissues by aromatization from androgen 
secreted by the adrenals and ovaries. The locally synthesized estrogen plays its role in 
situ, and only the part escaped from local metabolism enters the circulation (Simpson 
2003). Serum levels of estrogen reflect the local metabolism (Labrie et al. 1997a).      
E2 is the most potent estrogen in premenopausal women, and its serum level 
fluctuates during the menstrual cycle. The circulating E2 is carried exclusively by 
protein, about 60% of which is transferred bound to sex-hormone-binding globulin 
(SHBG), about 20% to albumin; about 20% remains, however, in its free form (Dunn et 
al. 1981, White & Porterfield 2013). The free form is the active one and can be taken up 
by other tissues. In the liver, E2 is converted to inactive metabolites, conjugated with 
sulfate or glucuronide, and excreted in the urine. Major metabolites of E2 consist of E1, 
E3, and catecholestrogens such as 2-hydroxyestrone and 2-methoxyestrone (White & 
Porterfield 2013).  
The estrogens, like other steroids, are derived from cholesterol that is an abundant 
structural component of plasma membranes and other organelles. The synthesis of E2 
involves a series of sequential modifications of the four fused rings of the sterol 
skeleton, which results in “the clipping of the side chain, alteration in olefinic bonds, 
and the addition of the hydroxyl function” (Strauss 2009). Accordingly, the pregnane, 
the androstane, and finally the estrone families are produced sequentially. Several 
classes of enzymes, primarily including the cytochromes P450, HSDs, and reductases, 
are involved in the process (Strauss 2009). In brief, the first three steps of the 
conversion are as follows: cholesterol—> pregnenolone—> 17-hydroxypregnenolone—> 
DHEA, which are catalyzed by the cholesterol side chain cleavage enzyme, 17a-
hydroxylase, and 17, 20-lyase, respectively. Androstenedione is formed from DHEA 
under the action of 3ß-HSD, which can form E1 directly or form E2 via an intermediate 
substrate, testosterone. Both of these two reactions are catalyzed by aromatase. The 
production of estrogen from DHEA is outlined in Figure 1.  
It is rare, however, that cells generate estrogen from cholesterol. Typically, estrogen 
biosynthesis requires the cooperative effects of two different tissues or cell types 
(Strauss 2009). One typical model is estrogen synthesis in the ovarian follicle. The 
theca cells produce androgen precursors, and this production is stimulated by 
luteinizing hormone. The granulosa cells carry out aromatization of the androgen into 
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estrogen, which is stimulated by follicle-stimulating hormone (FSH). Another model is 
the placenta, which needs precursors secreted by other tissues in order to synthesize 
estrogen. The fetal adrenal gland produces abundant DHEA-sulfate, which is secreted 
and taken up by the placenta. In syncytiotrophoblasts, DHEA-sulfate is converted to 
free DHEA, which is further aromatized into estrogen. In other peripheral tissues, such 
as brain, adipose tissue, and bone, the aromatization of androgen to estrogen also takes 
place similarly. The hormone precursors, DHEA and DHEA-sulfate, are therefore very 
important for estrogen formation (Labrie et al. 2005). 
 
 
 
Figure 1. Schematic illustration of DHEA metabolism. 4-adione, 4-androstenedione; 5?-adione, 5?-
androstanedione; A, 5?-androstan-3?-ol-17-one; 3?,5?-adiol, 5?-androstane-3?,17?-diol; 5?-
DHT, 5?-androstan-17?-ol-3-one; 3?,5?-adiol, 5?-androstane-3?,17?-diol; 3?,5?-adiol-17?, 
5?-androstane-3?,17?-diol; epiA, 5?-androstan-3?-ol-17-one; LCAT, lecithin-cholesterol 
acyltransferase. 1, 3? hydroxysteroid dehydrogenase (HSD)-1; 2, 5? reductase-1 and 5? 
reductase-2; 3, 3? HSD-1 and 3? HSD-3; 4, 3? HSD-4; 5, 3(???)-hydroxysteroid epimerase 
(HSE); 6, 17? HSD-2 and 17? HSD-4; 7, 17? HSD-1; 8, 17? HSD-2; 9, 17? HSD-3,5,13; 10, 
3? HSD-1; 11, 17? HSD-7 and [3(???)-HSE]. Reprinted with publisher's permission from 
the article that is Study I and based on the data from Labrie et al. (2005).  
2.2 17?-estradiol (E2) and dehydroepiandrosterone (DHEA) fatty 
acyl esters 
2.2.1 Formation of E2 and DHEA fatty acyl esters  
Formation in blood by LCAT and transfer between lipoproteins 
Steroid fatty acyl esters, such as E2 and DHEA fatty acyl esters, belong to a unique 
family of naturally occurring lipophilic derivatives of steroids, and whereas they were 
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synthesized in most tissues in vitro (Hochberg 1998, Vihma & Tikkanen 2011), the 
existence of E2 fatty acyl esters in human blood was originally detected by Janocko and 
Hochberg (1983, 1986). The endogenous E2 and DHEA fatty acyl esters were detectable 
in several tissues in men (Larner et al. 1985, Bélanger et al. 1994, Bélanger et al. 1990, 
Vihma et al. 2001, Badeau M et al. 2007) and in animals (Bélanger et al. 1990, Liere et 
al. 2004). The identification of the enzyme regulating the esterification of steroid has 
been carried out only in blood (Pahuja & Hochberg 1995, Lavallée, et al. 1996b, Kanji et 
al. 1999, Höckerstedt et al. 2002) and in human ovarian follicular fluid (Roy & 
Bélanger 1989b, Larner et al. 1993). In blood, E2 as well as DHEA was esterified in a 
reaction catalyzed by LCAT present in HDL subfraction 3 (HDL3) and then 
incorporated into HDL particles (Kanji et al. 1999, Höckerstedt et al. 2002). LCAT is 
responsible for the synthesis of cholesteryl esters in blood, which catalyzes the 
esterification of cholesterol at the carbon-3 position. Similarly, DHEA was also 
esterified at the carbon-3 position. However, E2 was a unique substrate of LCAT, and 
was esterified only at the D ring 17ß-hydroxyl group in both blood and tissue (Schatz & 
Hochberg 1981, Mellon-Nussbaum et al. 1982). Only E2 fatty acyl monoester was 
formed. After formation in HDL, similarly to cholesteryl esters, E2 and DHEA fatty acyl 
esters were subsequently transferred to LDL and VLDL fractions. In this transfer 
process, E2 fatty acyl esters, but not DHEA fatty acyl esters, at least partly rely on the 
activity of cholesterol ester transfer protein (CETP) (Provost et al. 1997, Helisten et al. 
2001). According to Roy and Bélanger (1989a), plasma lipoproteins contained more 
than 90% of circulating DHEA fatty acyl esters, 46% of which was found in LDL and 
37% in HDL. Similarly, most circulating E2 fatty acyl esters bind to lipoproteins (Larner 
et al. 1987, Vihma et al. 2003b).   
Formation in other tissues and the effect of Acyl coenzyme A: 17ß-estradiol transferase  
Although no specific enzyme has been characterized, the properties of the enzyme(s) 
catalyzing the formation of E2 fatty acyl esters were investigated in several tissues, such 
as human and rat mammary tumor tissue (Abul-Hajj 1982, Larner et al. 1985), rat liver 
(Pahuja & Hochberg 1995), and bovine adrenal and placenta (Martyn et al. 1988, Paris 
& Rao 1989). The acyl coenzyme A:estradiol-17ß acyltransferase was shown to be a 
membrane-bound enzyme with a optimum PH value of 5.0. Its substrate range is wide, 
including E2, DHEA, testosterone, and 5-androstene-3ß, 17ß-diol. As LCAT is 
responsible for the esterification of cholesterol and steroids in blood (Pahuja & 
Hochberg 1995, Kanji et al. 1999, Höckerstedt et al. 2002), it is reasonable to assume 
that acyl coenzyme A:cholesterol acyltransferanse (ACAT), which is responsible for the 
esterification of cholesterol in tissue, would also work on the esterification of steroids. 
Pahuja & Hochberg (1995) studied the esterifying enzymes for E2, DHEA, and 
cholesterol in plasma and in hepatic microsomes in rats. They found that, the ACAT 
inhibitor had no effect on the esterification of steroids in liver microsomes. Moreover, 
between steroid fatty acyl esters and cholesteryl esters, the fatty acid composition 
differed. They concluded that the esterification of E2 in rat liver microsomes was 
catalyzed by distinct enzyme(s) rather than by ACAT. Hochberg’s group (Kanji et al. 
1999) further studied ACAT activity in microsomal fraction from human adipose tissue 
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and placenta and showed the rate of E2 esterification in human adipose tissue to be 
higher than that in placenta and plasma (approximately 20 times and 4 times as high).  
Xu et al. (2001) have explored the esterification of E2 and other steroids using 
experimental female rat models. With stearoyl-CoA as the donor of long-carbon chain, 
liver microsomes had the highest fatty acyl-CoA:estradiol acyltransferase activity for E2 
esterification, followed by testosterone and DHEA, pregnenolone, and cortisosterone. 
Among various rat tissues, brain had the highest rate of E2 esterification, as compared 
to lung, uterus, liver or kidney, although esterification activity did not differ between 
brain cortex, brain cerebellum, and brain stem. These data were in line with findings 
showing that the esterification of DHEA and pregnenolone was higher in brain than in 
other tissues (Smith & Watson 1997), despite converse results by Hochberg with 
coworkers (Schatz & Hochberg 1981, Pahuja & Hochberg 1989). In addition, when a 
comparison of fatty acyl-CoA:estradiol acyltransferase activity in subcellular fractions 
from the rat liver was carried out, the liver microsomal fraction had the highest specific 
activity of acyltransferase, followed by lysosomal fraction, the nuclear fraction, and the 
mitochondrial fraction; little or no activity was observable in the hepatic cytosolic 
fraction (Xu et al. 2001). The rate of synthesis of E2 fatty acyl esters in rat liver was 
stimulated by the administration of clofibrate and gemfibrozil, but little or no effect 
emerged for other extrahepatic tissues, such as fat tissue and mammary glands (Xu et 
al. 2001, 2002).   
 
 
 
 
Figure 2. Formation of steroid and cholesteryl fatty acyl esters. LCAT, lecithin-cholesterol 
acyltransferase, catalyzes the esterification reaction in the systemic circulation; 
ACAT, acyl coenzymes A:cholesterol acyl transferase, catalyzes intracellular 
esterification reactions.   
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2.2.2 De-esterification of E2 and DHEA fatty acyl esters 
Fatty acyl esters of E2 and DHEA, like other steroid esters, do not act directly at the 
level of the receptor and are hormonally inactive (Janocko et al. 1984). Prior to any 
hormonal actions, they need to be hydrolyzed to the parent free steroid. In addition, 
they are considered resistant to metabolism. Thus, enzymatic hydrolysis by esterase is 
critical to both their endocrine actions and their catabolism. Recently, many studies 
have attempted to identify the esterase(s). At first, the non-specific esterases acting on 
the short-chain esters of E2 (such as E2 acetate) were examined as the potential 
candidates. However, using an MCF-7 breast cancer cell line, Katz et al. (1987) have 
shown that the enzyme catalyzing the hydrolysis of the long-chain fatty acyl esters of E2 
was distinct from that of non-specific esterases. This indicated the presence of a more 
specific esterase.  
Banerjee et al. (1990, 1991) have isolated an esterase from human breast cyst fluid 
that could cleave E2 esters. This esterase had a molecular weight of about 90~95 kDa 
and the properties of a B type carboxylesterase. A further study (Levitz et al. 1992) 
showed that esterase activity in breast cyst fluids derived from 384 women varied 
widely, with significant activity in only 39%. The authors speculated that such high 
esterase activity could be considered as indicating a risk of breast cancer in patients 
with fibrocystic disease. Xu et al. (2001) have compared the esterase activity for E2 
oleate in cytosol and microsomes in liver, fat, and mammary glands in rats. Fat tissue 
had higher esterase activity than did the liver. With clofibrate administration, 70 to 
107% higher esterase activity occurred in fat and liver, and ~40% higher in mammary 
glands (Xu et al. 2001). 
HSL is principally involved in adipocyte triglyceride hydrolysis and has broad 
substrate specificity (Holm 2003). Apart from adipose tissue, HSL is expressed in 
steroidogenic tissues such as adrenal and ovary (Kraemer & Shen 2002, Kraemer et al. 
2002), and its activities are under the control of hormones such as insulin and cyclic 
adenosine monophosphate (cAMP) functioning as the second messenger (Holm 2003). 
Lee et al. (1988) have compared the esterase activity of bovine placental cotyledons 
with HSL isolated from bovine adipose tissue. Using E2 oleate and DHEA oleate 
substrates, they showed that the hydrolysis of steroid fatty acyl esters was catalyzed by 
the esterase isolated from bovine placenta and by HSL of bovine adipose tissue. In 
addition, the enzyme responsible for the hydrolysis of E2 fatty acyl esters in the 
placenta was very similar to HSL in bovine adipose tissue. However, the possibility that 
more than one esterase existed in this tissue cannot be excluded because the isolated 
esterase was impure. Adams et al. (1991) have investigated esterase activity for E2 fatty 
acyl esters in breast tumor tissue and breast cancer cell lines, showing that the 
hydrolysis rate of E2 fatty acyl esters was, however, unaffected by addition of E2, 
dibutyryl cAMP, or calcitonin. Their data suggest that the esterase in human mammary 
cancer cells is a serine esterase but is not cAMP dependent, distinct from the one 
detected in bovine placenta and adipose tissue (Lee et al. 1988). However, the 
possibility that the enzymes could exist exclusively as phosphorylated forms in cultured 
cell models cannot be excluded. 
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2.2.3 The physiological role of E2 and DHEA fatty acyl esters 
Potent sex steroids 
Although their physiological role remains unclear, the E2 fatty acyl esters display long-
acting estrogenic effects. In experimental rat models, esterified E2 displays long-acting 
estrogenic effects, regardless of whether injected in aqueous alchohol or in oil (Larner 
et al. 1985, Vazquez-Alcantara et al. 1985, 1989). Moreover, the enhanced potency of E2 
monoester in carbon-17 is higher than that of E2 monoester in carbon-3 and E2 diesters 
(Vazquez-Alcantara et al. 1989). E2 fatty acyl esters do not, however, bind to estrogen 
receptor except at a hugely high concentration (Janocko et al. 1984). It is probable that 
the enhanced actions of E2 fatty acyl esters are due to an increased resistance to 
catabolism. Accordingly, in rats, the half-life of E2 carbon-17 fatty acyl esters was more 
than 6 h, while that for free E2 was 2 min (Larner & Hochberg 1985). In men, the 
protection of E2 esters from metabolic conversion also emerged (Janocko et al. 1984). 
Therefore, E2 fatty acyl esters have the ability to be converted, via hydrolysis, to free E2, 
which is attributable to their biological activity (Janocko et al. 1984, Hershcopf et al. 
1985). 
More recently, Paris et al. (2001) have shown that E2 17-stearate, after oral 
administration into juvenile female rats, is metabolized more slowly and can induce a 
stronger uterotrophic effect than can unesterified E2. This suggests a slower but 
sustained absorption of E2 liberated from E2 17-stearate or a facilitated transfer of 
esters in the lymphatic circulation, or both. Mills et al. (2001) have investigated the 
stimulatory effect of subcutaneous administration of E2 17-stearate on the growth of 
mammary and uterine tissues in ovariectomized female rats. They determined the 
growth of mammary glandular cells and uterine cells by measuring the 5-bromo-2?-
deoxyuridine-labeling index. Compared to E2 at equal molar doses, E2 17-stearate had a 
stronger stimulative effect on mammary cell proliferation, and inversely, less effect on 
uterine endometrial cell proliferation. The authors concluded that esterified E2 
appeared to have a stronger mitogenic effect on fat-rich mammary tissue. They further 
speculated that lipophilic E2 fatty acyl esters might accumulate in the adipose tissue 
surrounding mammary glandular cells and then they act continuously after hydrolysis. 
Thus, the availability of the biologically active E2 may be regulated by differing local 
esterase activity. Accordingly, the same group detected a higher estrogen esterase 
activity in the breast than in uterine tissue (Mills et al. 2008). E2 fatty acyl esters in 
female rats could also more effectively induce mammary tumor than uterine and 
pituitary tumors (Mills et al. 2008). 
Antioxidative function 
Shwaery et al. (1997, 1998) explored the association of radiolabeled E2 and LDL and its 
effect on protection of LDL from oxidation in vitro. They showed that E2 at 
physiological concentrations (10 nmol/l) was esterified and incorporated into LDL 
during their incubation with plasma. Then the esterified E2-containing LDL may 
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increase resistance against Cu2+-mediated oxidation. In addition, the nonesterified E2 
causes increased resistance to LDL oxidation at a much higher concentration (?1 
μmol/l) (Shwaery et al. 1997). This raised the possibility that fatty acylation of E2 may 
lead to the increased antioxidative potential of E2. Kuohung et al. (2001) have 
demonstrated that E2 fatty acyl esters, together with tamoxifen and physiological 
concentration of E2, could reduce the oxidation of LDL mediated by endothelial cells. 
However, this antioxidant effect of a physiological concentration of esterified E2 has not 
been confirmed elsewhere. Meng et al. (1999) and Höckerstedt et al. (2004) have 
reported that the incorporation of E2 fatty acyl esters into lipoproteins (HDL and LDL) 
may enhance the antioxidative resistance of these particles, but this effect can be 
attained only at very high concentrations. 
Lipoprotein-associated steroid fatty acyl esters as hormone precursors 
The circulating lipoprotein-incorporated pregnenolone and DHEA fatty acyl esters, 
after their entry into target cells, serve as steroid substrates (Provencher et al. 1992, 
Roy & Bélanger 1992, 1993). HDL- or LDL-associated pregnenolone fatty acyl esters are 
internalized by porcine granulosa cells and further converted to free pregnenolone, 
progesterone, and various metabolites of progesterone (Roy & Bélanger 1992). 
Moreover, the administration of gonadotrophic hormone can raise the production of 
progesterone. This indicates that the formation of progestins from these substrates is 
under hormone regulation (Roy & Bélanger 1992). Later, the same group reported that 
LDL-incorporated esterified DHEA can be delivered into ZR-75-1 breast cancer cells via 
a lipoprotein receptor-mediated pathway, after which nonesterified DHEA and 
androst-5-ene-3?,17?-diol are produced in these cells (Roy & Bélanger, 1993).  
Similar findings have been observed regarding lipoprotein-associated E2 fatty acyl 
esters. Badeau RM et al. (2007) investigated the cellular uptake mechanism of HDL-
incorporated E2 fatty acyl esters and their potential conversion to biologically active E2 
in Fu5AH rat hepatoma cells. They showed that HDL-incorporated radiolabeled E2 
fatty acyl esters are rapidly taken up by the hepatic cells. Cellular uptake is in part 
mediated by scavenger receptor class B, type I (SR-BI) and LDL receptors. During 24 h 
incubation, approximately half of the intracellular radioactivity is recoverable as 
unesterified E2 and the other half as esterified E2, indicating the existence of esterase 
activity. Interestingly, Gong et al. (2003) showed that HDL-associated E2 is delivered to 
endothelial cells via SR-BI. After uptake, HDL-associated E2 raises the production of 
nitric oxide synthase in endothelial cells and then induces vasorelaxation. Brodeur et al. 
(2008) demonstrated that radiolabeled E2 incorporated into LDL and HDL3 was 
selectively transferred into osteoblastic cells, which expressed several SR-B receptors 
(SR-BI, SR-BII, and CD 36). The selective uptake of LDL- or HDL-associated 
radiolabeled E2 could be partially inhibited by competitive SR-B ligands: HDL or LDL 
and oxidized LDL particles. In these studies, the authors did not discuss the possibility 
that the lipoprotein-bound E2, in fact, may be in fatty acyl ester form (Badeau M et al. 
2008).  
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2.3 Quantitative measurement of E2 and DHEA fatty acyl esters  
2.3.1 Quantitative measurement of free E2 and DHEA 
Immunoassay-based methods 
Abraham established the first radioimmunoassay (RIA) method for E2 in 1969. This 
analysis method consisted of several purification steps (including organic solvent 
extraction and Celite or Sephadex column chromatography) and final RIA 
determination of E2. Organic solvent extraction and chromatography purification 
allowed removal of the conjugated steroids and the E2 metabolites, respectively. This 
RIA method was sensitive, specific, precise, and accurate. Soon afterwards, methods for 
determining steroid hormones such as testosterone and DHEA were developed 
accordingly. To improve the assay sensitivity, tritium in the radioactive markers was 
replaced with iodine. Since then, these RIA methods have been widely used in clinical 
and research laboratories. However, the major drawbacks are the time-consuming, 
cumbersome work with radioactive material and the high cost.  
Direct immunoassays, simpler and faster than RIA, were established in the late 
1970s. The nonradioactive ligands (chemiluminescent, enzymatic, or fluorescent) 
replaced the radioligand in RIAs, making rapid measurements possible. Although they 
have plenty of advantages, these assays have several major disadvantages. First, due to 
the lack of specificity of the antibody, they often overestimate the measurements 
(Stanczyk et al. 2010). Second, matrix differences may exist between serum samples 
and solutions of the standard used to prepare the standard curve in the assay, which 
also affects the validity of the results. Finally, direct immunoassays generally lack 
sensitivity to measure low levels of E2 with accuracy and reliability, such as samples 
from men and from postmenopausal women (Stanczyk et al. 2007). 
An important concept in validating an immunoassay is assay sensitivity, which is 
defined as its minimal detection limit (Findlay et al. 2000). From a practical 
standpoint, it is the lowest concentration of a standard (on the standard curve) that can 
be distinguished from the zero standard and is based on the confidence limits of the 
measurements. The measurements below assay sensitivity are unreliable and should 
not be considered valid for statistical analysis (Stanczyk & Clarke 2010). However, in 
the literature reporting steroid hormone concentrations, the authors did not always 
explain in detail how the assay sensitivity and quality control were calculated (Stanczyk 
& Clarke 2010).   
Measurement with mass spectrometric methods 
Mass spectrometric methods such as GC–MS and LC–MS/MS were developed to 
measure steroids even earlier than the immunoassay development (Sweeley &, Horning 
1960). Because of its high sensitivity and precision, LC–MS/MS has been considered 
the gold standard for steroid quantification. Compared to mass spectrometric methods, 
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immunoassays were revealed to give higher values, especially in analysis of lower 
concentrations of E2.  
A recent large cohort study compared concentrations of E2 and testosterone 
determined by both mass spectrometry and commercial immunoassays in over 3000 
men (Huhtaniemi et al. 2012, Mitchell 2012). According to their data on eugonadal and 
hypogonadal men, measurement of serum testosterone levels by routine immunoassay 
methods was as reliable as by an in-house GC–MS method. However, for the detection 
of serum E2, the mass spectrometric method appeared to have higher sensitivity than 
did the immunoassay method. Especially when low E2 levels (<40.7 pmol/l) were 
analyzed, a particularly poor correlation appeared between these two methods, and the 
immunoassay analysis displayed only 13.3% sensitivity compared with the mass 
spectrometry method.   
A review article (Stanczyk & Clarke 2010) compared the advantages and 
disadvantage of gas chromatography (GC) and liquid chromatography (LC), two 
common chromatographic methods to separate the analyte from the matrix and 
introduce it to mass spectrometry (MS). GC is an effective technique that allows 
baseline resolution of minor structural differences between analytes. It needs only a 
small volume of samples to be injected, typically 1 to 5 μl. However, due to the small 
volume injected, the sample needs to be extensively purified prior to analysis in order 
to obtain enough intensity of the analyte. The runtimes are long (usually 30 min or 
more), and non-volatile substrates (such as steroid) require chemical derivatization. 
Conversely, LC cannot provide as high resolution as does GC, and thus the former may 
have difficulties in separating analytes, although it is possible. Moreover, a specific 
detector is needed, due to the poor resolution. However, chemical derivatization is 
unnecessary because samples are already in a liquid form. LC can provide fast analysis. 
LC–MS/MS has therefore been widely used in determining steroid hormones in clinical 
and research laboratories, but the advantage of the GC–MS assay is its providing better 
chromatographic resolution and even sensitivity (Krone et al. 2010). GC–MS and GC–
MS/MS assays are capable of measuring large numbers of structurally similar analytes. 
2.3.2 Quantitative measurement of E2 and DHEA fatty acyl ester derivatives 
Quantitative analysis of E2 fatty acyl esters 
Larner and colleagues (1992) were among the first to quantify concentrations of E2 fatty 
acyl esters in several tissues in human subjects. They validated a GC–MS-based 
quantitative method for analyzing hydrolyzed E2 fatty acyl esters prepared by 
saponification and chromatography purification. In their study, the concentration of E2 
esters in blood was very low, quantifiable in only six of ten premenopausal women, in 
the range 7 to 169 pmol/l. In three premenopausal women undergoing gonadotrophin 
treatment, the levels of esterified blood E2 were 48, 57, and 92 pmol/l. The esterified E2 
in blood was, however, undetectable in postmenopausal women and in men. In both 
subcutaneous and visceral adipose tissue in premenopausal women, rather high levels 
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of E2 esters were detectable (154–2834 fmol/g tissue).  After menopause, the levels of 
esterified E2 in both depots of fat were quantifiable in most of the subjects, ranging 
between 246 and 1406 fmol/g tissue. No significant difference in esterified E2 
concentration emerged between these two depots of fat tissues nor between pre- and 
postmenopausal women.  
Vihma et al. (2001) have recently established a TR-FIA-based method for 
quantifying E2 fatty acyl esters in serum and in ovarian follicular fluid. The quantitative 
method includes saponification, several chromatography purification steps, and TR-
FIA determination of E2 after hydrolysis of E2 esters. The median of E2 fatty acyl ester 
concentration in serum from young women was 75 pmol/l, from postmenopausal 
women 80 pmol/l; in men it was 52 pmol/l. In women, the median ratio of serum E2 
ester to E2 was the highest in postmenopause, intermediate in premenopause, and the 
lowest in pregnancy (Vihma et al. 2001, 2003a, 2004). This suggests that the 
proportion of esterified E2 in the circulation may increase with decreasing serum E2 
levels. The same group further quantified the concentrations of esterified E2 in different 
lipoprotein fractions (Vihma et al. 2003b). The mean concentration of E2 fatty acyl 
esters in VLDL was 89 pmol/l, LDL 143 pmol/l, HDL2 148, and HDL3 137 pmol/l. Most 
E2 fatty acyl esters were recovered in HDL (54%) and LDL (28%) fractions. The 
esterified E2 concentrations in lipoproteins were 75% of serum levels. In contrast, free 
E2 concentration in total lipoproteins was 0.2% of that in serum. This finding is in line 
with the data on quantifying the distribution of esterified DHEA in different 
lipoproteins (Roy & Bélanger 1989a). 
Badeau M et al. (2007) modified the TR-FIA method and utilized it to measure 
concentrations of E2 fatty acyl esters in adipose tissue and serum from women in late 
pregnancy, from non-pregnant premenopausal women, and from postmenopausal 
women. Serum concentrations of free E2 in these three groups were in agreement with 
their hormonal status, i.e, high in pregnancy, intermediate in premenopause and very 
low in postmenopause (71.4 vs. 0.48 vs. 0.05 pmol/l, median concentration). Serum 
esterified E2 concentrations were in line with earlier figures from TR-FIA-based 
methods (Vihma et al. 2001, 2003a, 2004). No site differences in the concentrations of 
E2 fatty acyl esters emerged among all three groups: pre- and postmenopausal women 
had comparable amounts of esterified E2 in both depots of fat. Pregnant women 
displayed their highest concentrations of esterified E2 in visceral fat and subcutaneous 
fat. The median ratio of esterified E2 to free E2 in visceral fat increased from 9.6% in 
pregnancy to 147% in premenopausal and 390% in postmenopausal women. The 
median concentration of esterified E2 in adipose tissue was at least 10 times as high as 
that in serum. In all of the premenopausal women, free E2 concentrations in adipose 
tissue were higher than those in serum.  
Esterified E2 was also quantified in breast cyst fluid (Larner et al. 1992) and ovarian 
follicular fluid (Vihma et al. 2001), however, little or none occurred in muscle or urine 
(Larner et al. 1992). 
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Quantifying DHEA fatty acyl esters  
By a radioimmunoassay method, the concentration of DHEA fatty acyl esters has been 
determined in the blood of men (Bélanger et al. 1994, Labrie et al. 1997b, Couillard et 
al. 2000) and in adrenal tissues in several species and in men (Bélanger et al. 1990), as 
well as in the brain of rats (Liere et al. 2004). Essentially, DHEA fatty acyl esters were 
determined as their hydrolyzed form after separation from the DHEA fraction, 
saponification, and chromatographic purification. Couillard et al. (2000) have studied 
the association between aging and plasma steroid concentrations in healthy men. Both 
DHEA fatty acyl esters and free DHEA decreased significantly in an age-related 
manner. The mean concentration of DHEA fatty acyl esters in men was 11.5 nmol/l (20- 
to 29-yr-old men) and 5.9 nmol/l (?50-yr-old men). The corresponding mean 
concentrations of nonesterified DHEA were 22.0 nmol/l and 7.9 nmol/l. However, the 
proportion of esterified DHEA to free DHEA in plasma increased during aging, in line 
with other earlier findings (Bélanger et al. 1994, Labrie et al. 1997b). To the best of our 
knowledge, concentration of DHEA fatty acyl esters has not been determined in adipose 
tissue. 
More recently, free DHEA concentration in serum has been determined by GC–MS 
(Labrie et al. 2006, 2007, 2011). Concentrations of serum DHEA in 442 
postmenopausal women were 2.03±1.33 ng/ml (mean±SD), which were widely 
distributed (5th and 95th centiles at 0.55 and 4.34 ng/ml, respectively, a 7.9-fold 
difference)  (Labrie et al. 2011).  
2.4 Estrogen metabolism in adipose tissue 
2.4.1 Synthesis of E2 in adipose tissue and obesity 
Adipose tissue expresses all the enzymes necessary for synthesis of estrogen and 
androgen from DHEA (Labrie et al. 1997a). Aromatase is responsible for the synthesis 
of E1 from testosterone and E2 from androsterone. 17ß-HSDs are involved in the 
conversion of E1 to E2. Adipose tissue is quantitatively important for estrogen formation 
in postmenopausal women and in elderly men. The expression and activity of these 
enzymes are strictly regulated, which affects the availablity of estrogen and androgen. 
In postmenopausal women, the production of E1 from testosterone increases with BMI 
and aging (Forney et al. 1981, Misso et al. 2005). Compared to non-obese men, obese 
men have shown higher mean concentrations of E2 and E1 in serum (Schneider et al. 
1979). As reported in a large cross-sectional study, the association of increased body 
fatness in men with increased serum total E2 concentrations was significant, after 
adjusting for serum testosterone and SHBG, both of which values decreased in obesity 
(Zumoff et al. 1981). The increased level of estrogen as a result of increased fat mass in 
obese subjects might play a role in their breast-cancer risk. In obesity, the increased 
adiposity and increased expression of aromatase in subcutaneous adipose tissue may 
lead to increased E2 levels in the circulation (Baglietto et al. 2009, Calle & Kaaks 2004). 
In addition, the elevated levels of serum insulin as a result of adipose tissue dysfunction 
may cause both increased ovarian androgen synthesis and decreased hepatic synthesis 
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of SHBG, in turn, elevating the bioavailable estrogen (Calle & Kaaks 2004). The fact 
that aromatase exists in the adipose tissue of the breast is the basis for the use of 
pharmacological aromatase inhibitors in treatment of breast cancer. 
As they are hydrophobic and fat soluble, E2 fatty acyl esters reportedly accumulate 
in adipose tissue. Concentrations of E2 fatty acyl esters in adipose tissue are higher than 
those of free E2 in both pre- and postmenopausal women (Badeau M et al. 2007). It is 
reasonable to speculate that the esterified E2 stored in adipose tissue may be the source 
of free E2 via hydrolysis. In bovine adipose tissue, HSL is responsible for this hydrolysis 
(Lee et al. 1988). On the other hand, the net balance between hormonally inactive E2 
fatty acyl esters and hormonally active E2 might play a role in breast-cancer risk as 
suggested in experimental rats (Paris et al. 2001, Mills et al. 2001, 2008).  
2.4.2 Differences in estrogen metabolism between subcutaneous and visceral 
adipose tissues  
Subcutaneous adipose tissue accounts for 80 to 90% of body fat, and visceral adipose 
tissue for 8 to 20% (Karastergiou et al. 2012). Abdominal subcutaneous and visceral 
adipose tissue appear to be distinct in terms of androgen metabolism in obese men 
(Bélanger et al. 2006), although less is known about the metabolism of estrogen in 
these two depots of adipose tissue. Blouin et al. (2009) have analyzed the expression 
levels of a large number of steroidogenic and steroid-inactivating enzymes and also the 
effects of adipocyte differentiation on the gene expression. They found higher 
expression levels in subcutaneous fat than in omental fat for 3ß-HSD type 1, for aldo-
keto reductase 1C3 and 1C2, and for androgen receptor. No differences in gene 
expression of P450 aromatase and steroid sulphatase (STS) emerged, however, between 
these two depots of adipose tissue. Induction of adipocyte differentiation leads to 
significantly increased expression levels in subcutaneous adipose tissue cultures for 
aldo-keto reductase 1C3 and 1C2, STS, estrogen receptor-ß, and the androgen receptor, 
but not for P450 aromatase. Gene expression and protein level of HSL compared 
between subcutaneous and visceral fat showed in both obese and lean women that 
subcutaneous adipose tissue contained higher levels of HSL mRNA than did visceral fat 
(Ray et al. 2009). However, another group reported no difference in HSL expression 
levels between subctaneous and visceral fat (Montague et al. 1998). The level of HSL 
protein does not differ between subcutaneous and visceral fat (Lundgren et al. 2008, 
Ray et al. 2009) or between sexes (Lundgren et al. 2008). HSL activity does not differ 
between subcutaneous and visceral fat in obese women (Ray et al. 2009), and in both 
depots of fat, and obese women have higher HSL mRNA levels but lower HSL protein 
levels than do lean women. Gender-wise, HSL mRNA levels are higher in obese women 
than in obese men (Kolehmainen et al. 2002).   
2.4.3 Effects of estrogen on adipose tissue 
Estrogen plays diverse roles in adipose tissue (Cooke & Naaz 2004). It is well 
documented that estrogen, together with progesterone and testosterone, plays a role in 
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the metabolism, accumulation, and distribution of adipose tissue (Simpson 2003, 
Cooke & Naaz 2004, Mayes & Watson 2004). E2 directly reduces adipose tissue 
deposition, and loss of estrogen signaling leads to an increased visceral fat amount, as 
seen in postmenopausal women (Cooke & Naaz 2004). Moreover, E2 raises the 
subcutaneous adipose tissue amount by reducing lipolysis via the a2A-adrenegic 
receptor-mediated mechanism (Pedersen et al. 2004). In addition, E2 inhibits adipose 
tissue deposition in males (Heine et al. 2000, Jones et al. 2001), and furthermore, 
estrogen may play a role in reducing the inflammatory response in adipose tissue 
(Turgeon et al. 2006). E2 has metabolic effects on other target organs that regulate 
adipose tissue by influencing energy intake and expenditure. Several groups reported 
that two estrogen receptors (estrogen receptor alpha, ER? and estrogen receptor beta, 
ERß) are expressed in adipocytes (Price & O'Brien 1993, Mizutani et al. 1994, Pedersen 
et al. 1996, 2001), suggesting the direct action of estrogen in adipose tissue. Evidence is 
increasing that estrogen carries out its actions via both genomic and non-genomic 
mechanisms. In the genomic pathway, estrogen binds to its nuclear receptor and then 
regulates the transcription of target genes. Lipoprotein lipase and leptin are two key 
proteins in adipose tissue which display a transcriptional response to steroid hormone 
control. Lipoprotein lipase is the key enzyme for the hydrolysis of circulating 
triglycerides into free fatty acids and glycerol (Goldberg & Merkel 2001), which plays a 
role in adipocyte lipid storage and muscle fuel supply and hence regulates muscle mass 
and obesity. Estrogen, together with growth hormone, appears to reduce lipid 
accumulation by reducing the expression and activity of lipoprotein lipase (Bjorntorp 
1996). Leptin is a protein hormone which plays a key role in the regulation of food 
intake, energy expenditure, and body weight homeostasis (Friedman & Halaas 1998). 
Estrogen may increase, and testosterone may decrease the synthesis and secretion of 
leptin, via sex-steroid receptor-dependent transcriptional mechanisms (Machinal et al. 
1999). Women have much higher blood leptin levels than men do (Armellini et al. 
2000), and these levels are independent of differences in body composition. 
Alternatively, estrogen may initiate rapid signaling events via a non-genomic 
mechanism in which estrogen binds to its receptor in the plasma membrane and 
induces several physiologically relevant second messengers. Using immunostaining, 
Anwar et al. (2001) detected both ER? and ERß in the cell membranes of subcutaneous 
abdominal and omental adipose cells. The second messengers include the cAMP 
cascades (Levin 1999, Kelly & Levin 2001, Dos Santos et al. 2002, Mayes & Watson 
2004, D'Eon & Souza et al. 2005), and many of their functions are connected to the 
regulation of adipose tissue metabolism. 
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3 AIMS OF THE STUDY 
The major aims of this study were as follows: 
 
1 To study the role of hormone-sensitive lipase (HSL) in regulating E2 and 
DHEA fatty acyl ester hydrolysis, the role of lysosomal acid lipase (LAL) in 
regulating DHEA fatty acyl ester hydrolysis and the metabolic fate of DHEA 
fatty acyl esters in cultured HeLa cells. 
 
2 To set up a quantitative method for analysis of DHEA and DHEA fatty acyl 
ester concentrations in adipose tissue and serum, and to study to what extent 
DHEA exists in human adipose tissue and what proportion of DHEA exists in 
fatty acyl ester form.  
 
3 To compare the esterification and de-esterification of E2 in human breast 
subcutaneous adipose tissue, and to explore how much free E2 is produced in 
adipose tissue.  
 
4 To quantify E2 fatty acyl ester and E2 concentrations in breast subcutaneous 
adipose tissue from women and in abdominal adipose tissue from obese men 
and women, and to quantify the expression levels of estrogen-regulating genes 
in adipose tissue in obese men and women.  
Materials and methods 
28 
4 MATERIALS AND METHODS 
4.1 Subjects and study design 
4.1.1 Lysosomal acid lipase (LAL) in DHEA-ester hydrolysis and DHEA fatty 
acyl ester concentrations in adipose tissue (Studies I and II) 
Blood samples came from healthy, normolipidemic female volunteers (6 pre- and 2 
postmenopausal women, Studies I and II). Samples of visceral adipose tissue (n=14) 
and blood (n=20) came from patients undergoing gynecological surgery for 
nonmalignant conditions (Study II).  
4.1.2 Esterification and de-esterification of E2 in adipose tissue (Study III) 
Samples of breast subcutaneous adipose tissue and blood came from women 
undergoing breast surgery for non-malignant reasons (reduction mammoplasty, n=27). 
Eight of the subjects were postmenopausal (median age, 56 yr; range, 53–68), and 19 
were premenopausal (median age, 45 yr; range, 32–53). Three postmenopausal 
subjects used systemic estrogen regimens (oral or transdermal) at the time of the 
operation, and three premenopausal subjects used estrogen-containing oral 
contraceptives. Three premenopausal women had vaginal ring-releasing estrogen and 
progestin or intrauterine (progestin) contraceptive devices, and one postmenopausal 
subject used topical vaginal estrogen. When a larger size of samples was needed, the 
adipose tissue was taken from women undergoing breast surgery for breast cancer 
(n=16). None of the cancer patients used systemic estrogen treatment on the day of the 
operation. One woman was premenopausal, but the others were postmenopausal.  
Adipose tissue from male Dark Agouti (DA, RT1av1) rats (Scanburg, Göteborg, 
Sweden) was kindly provided by Dr. R. Tuuminen (Transplantation Laboratory, 
University of Helsinki). Permission for animal experimentation was granted by the 
State Provincial Office of Southern Finland. The rats were treated according to the 
“Guide for the Care and Use of Laboratory Animals”, prepared by the National 
Academy of Sciences and published by the National Academy Press (ISBN 0-309-
05377-3; revised 1996).  
4.1.3 Concentration of E2 and E2 fatty acyl esters and expression levels of 
estrogen-regulating enzymes in obese subjects (Study IV) 
Study subjects included 14 obese men and 22 obese women who were undergoing 
gastric bypass surgery (Table 1). None had diabetes but 13 (9 women and 4 men) had 
impaired glucose tolerance (plasma glucose 7.8–11.1 mmol/liter at 2 h in 2 h oral 
glucose tolerance test). Half of the study subjects (n=18) were using antihypertensive 
medications. None of the women were receiving systemic estrogen or progestin 
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regimens, but five used intrauterine progestin-releasing contraceptive devices. Ten 
women undergoing elective abdominal gynecological surgery for nonmalignant reasons 
were recruited to the study as controls (Table 1).  
 
 n Age (yr) BMI (kg/m2) HbA1c (%) fS insulin (mU/l) 
Obese men 14 46 (31-59) 50 (34-63) 5.7 (5.1-6.2) 19 (6.4-29) 
Obese women 22 41 (29-49) 48 (37-63) 5.7 (4.8-6.3) 14 (3.8-20) 
Control women 10 44 (40-47) 28 (22-31)   
 
Table 1. Clinical characteristics of study subjects in Study IV. The data are expressed as median 
(range). HbA1c, glycated haemoglobin; fS insulin, fasting serum insulin. Reprinted with 
publisher's permission from the article that is Study I. 
 
4.2 Materials and methods 
4.2.1 List of published methods  
The methods used in this thesis are listed in the Table below in alphabetical order. The 
original publications in which the methods appear are indicated by their Roman 
numerals.   
 
Method Original study 
Bligh-Dyer lipid extraction III 
Cell culture I 
Esterase activity assay in adipose tissue III 
Esterification assay of steroids in adipose tissue III 
GC–MS determination of DHEA II 
Hydrophobic chromatography I-IV 
Incubation of LDL-associated [3H]DHEA fatty acyl esters with cultured cells   I 
Isolation of lipoproteins I 
LC–MS/MS determination of E2 III and IV 
LC–MS/MS determination of DHEA II 
Lipid extraction I-IV 
Lowry protein determination (Lowry et al. 1951) I and III 
Materials and methods 
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Preparation of LDL-associated [3H]DHEA- and [3H]cholesteryl esters I 
Quantitative real-time PCR IV 
Quantitative determination of DHEA fatty acyl esters II 
Quantitative determination of E2 fatty acyl esters III and IV 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE),  
Western blotting, and enhanced chemiluminescence (ECL) 
I 
 
Size-exclusion chromatography I 
Ribonucleic acid interference (RNAi) I 
Thin layer chromatography (one and two-dimensional TLC) I and III 
TR-FIA determination of E2 III and IV 
4.2.2 Instrumentation 
E2 TR-FIA was carried out with the instruments from Wallac Oy (DELFIA Platewash, 
DELFIA Plateshake, and Victor 1420 counter with a software version for time-resolved 
fluorescence measurements; Turku, Finland). The Wallac 1409 liquid scintillation 
counter and Wallac 1420 Victor2 multilabel counter (also from Wallac Oy) served for 
determining radioactivity and protein amounts, respectively. 
The GC–MS system consisted of the Fisons Instrument MD 1000 quadrupole mass 
spectrometer and GC 8000 gas chromatograph (Fisons Instrumentation, Inc., Milan, 
Italy). Separation was performed with a BP-1 column (length 15 m, I.D. 0.22 mm, film 
thickness 0.25 m; SGE International Pty Ltd., Ringwood, Australia) with helium as the 
carrier gas (flow 1 ml/min). Data acquirement and process was carried out with the 
XcaliburConfig MFC Application (version 1.0.0.1).  
The LC–MS/MS was an API 4000 triple quadrupole mass spectrometer (MSD or 
AB Sciex, Concord, CA, USA), using an Agilent series 1200 HPLC system with a binary 
pump (Agilent Technologies, Waldbronn, Germany) and a SunFire C18 column (2.1?
100 mm; 3.5 μm; Waters, Milford, MA, USA) as peripherals. The Analyst Software 
(MSD or AB Sciex) served in acquiring and processing the data. 
Lipoprotein fractions were isolated by ultracentrifugation with the Bechman 
Optima LE-80K ultracentrifuge using a Ti 50.4 rotor (Brea, CA, USA). The fat tissue 
samples were homogenized with an Ultra Turrax T8 homogenizer (IKA-Werke, 
Staufen, Germany). The location of the [3H]labeled sample was determined by the 
Cyclone Storage Phosphor System with OptiQuant software (Packard Instrument, 
Meriden, Connecticut, USA). 
Quantitative real-time PCR was performed by an ABI 7900 Sequence Detection 
System instrument and software was from Applied Biosystems (Foster City, CA, USA). 
The RNA concentration and quality was analyzed with a NanoDrop ND-1000 
Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA) or 2100 
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Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Hydra 96 Microdispenser 
was from Robbins Scientific (Sunnyvale, CA, USA). 
4.2.3 Sample collection and storage 
The human abdominal fat tissue samples (visceral fat and subcutaneous fat) and breast 
subcutaneous fat tissue samples (one specimen each from two of four quadrants of the 
breast–for breast cancer patients, one quadrant being near the tumor, and another 
quadrant, far from the tumor) were taken during the operation and immediately snap-
frozen in liquid nitrogen. The rat adipose tissue was also taken during the operation 
and immediately snap-frozen in liquid nitrogen. The blood samples were taken from 
patients before the operation or from healthy volunteers after overnight fasting. Serum 
was separated by centrifugation within 1 h. The fat tissue samples (both from human 
beings and rats) were stored at ?80 °C and serum samples at ?20 °C until analysis.   
Plasma lipoproteins were isolated by sequential ultracentrifugation (Havel et al. 
1955). Very low-density lipoprotein (VLDL)-free plasma was prepared as follows: 
plasma was centrifuged at 2500 g for 15 min at +4 °C. After isolation of the VLDL 
fraction from plasma at a density of d < 1.006 g/ml (270,000 g, 3.5 h, 10°C), the VLDL-
free plasma was stored at ?20°C until further use. 
4.2.4 Control serum samples (Studies III and IV) 
Low, medium, and high control serum samples were prepared as described by Vihma et 
al. (2001): pooled male sera (Sigma, St. Louis, MO, USA) were spiked with different 
concentrations of E2 17-stearate, corresponding to E2 concentrations of 110 pmol/l, 257 
pmol/l and 598 pmol/l. 
4.2.5 Hydrophobic chromatography and TLC analyses of DHEA metabolites 
and DHEA-ester hydrolysis (Study I) 
To separate [3H]DHEA fatty acyl esters from free [3H]DHEA and its metabolites, the 
lipid extracts from media and cells (in 0.3 ml cyclohexane-toluene-methanol, 6:4:1, 
v:v:v) were applied to a Sephadex LH-20 column (1.2×7.2 cm) and eluted with 20 ml of 
the same solvent. Twenty fractions of 1 ml per fraction were collected, and radioactivity 
in each fraction was determined. When labeled standards were analyzed, the nonpolar 
fraction (DHEA fatty acyl ester) was eluted at the 4th to 7th fractions and polar fractions 
(free DHEA and its metabolites) were eluted at the 12th to 18th fractions with their peak 
at the 15th fraction.  
To identify the metabolites of DHEA, one- and two-dimensional TLC (TLC 3 and 
TLC 4, Table 3) were used. The cellular and medium fractions were first purified by LH-
20 chromatography as described above and then applied to TLC, with references listed 
in Table 3. After running and drying at room temperature, the locations of the 
standards were determined by ultraviolet light with rhodamine staining, and the 
locations of the samples containing [3H] label were detected by the Cyclone Storage 
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Phosphor System with OptiQuant software. The TLC plates were exposed to the [3H]-
sensitive screen for 3 days.  
The samples from experiments exploring the role of LAL in the hydrolysis of DHEA 
fatty acyl esters in cultured cells were analyzed with TLC 1 (Table 3). After rhodamine 
staining of the locations of the nonlabeled standards, the locations of the samples 
containing [3H] label were determined by scraping 1 × 1- or 1 × 1.5-cm strips, followed 
by transfer of the material to vials in 500 μl methanol for liquid scintillation counting, 
with strips of clean plate serving as blanks.   
 
TLC TLC standards TLC running solvent 
TLC 1 DHEA and DHEA oleate Hexane: ethyl acetate (50:50, v:v) 
TLC 2 Cholesterol and cholesteryl 
esters 
Hexane: diethyl ether: acetic acid (80:20:1, 
v:v:v) 
TLC 3 [3H]DHEA linoleate, and 
[3H]DHEA 
Hexane: ethyl acetate (70:30, v:v)  
TLC 4 DHEA oleate, DHEA, 5?-
androstanedione (5?-adione), 
and 4-dione  
First run, hexane: ethyl acetate (50:50, v:v); 
second run, dichloromethane: acetone 
(92.5:7.5, v:v) 
  
Table 3.  TLC analyses of DHEA metabolites and LAL-mediated hydrolysis of DHEA fatty acyl esters.  
TLC was run on silica gel G-60, except that TLC 3 was run on a RP-8 F254 s plate.  TLC 2 was 
run as a control using cholesterol and cholesteryl esters.     
4.2.6 Quantification method for DHEA fatty acyl esters (Study II) 
Separation and purification of DHEA fatty acyl esters and free DHEA 
Figure 3 shows the outline of the method to quantitate DHEA fatty acyl esters. In short, 
~400 mg of the visceral fat samples were thawed, rinsed, and homogenized in 1 ml 
distilled water. With addition of internal standard ([3H]DHEA linoleate, [3H]DHEA 
oleate or [3H]DHEA fatty acyl esters) in 5—10 μl hexane to each sample, the samples 
were extracted four times with 4.5 ml of diethyl ether. The DHEA fatty acyl esters and 
free DHEA were further separated by use of Sephadex LH-20 chromatography 
(0.5 ? 6 cm in Pasteur pipettes), in which the DHEA fatty acyl ester fraction was eluted 
by 4 ml of hexane, and free DHEA was eluted with 5 ml of hexane: chloroform (1:1, v:v). 
After evaporation to dryness, free DHEA fractions were stored at -20 °C until further 
analysis, and DHEA fatty acyl ester fractions were subjected to saponification. The 
saponification was carried out in methanolic KOH at 60 °C for 2 h, after which 1 ml 
water was added to each sample, and the pH value was adjusted to 3 with hydrochloric 
acid. The hydrolyzed DHEA fatty acyl esters were extracted and further purified with 
second Sephadex LH-20 chromatography on a larger column (1?6 cm). After washing  
 33 
 
 
 
 
Figure 3. Workflow of the quantitative DHEA fatty acyl ester method. Reprinted with publisher's 
permission from the article that is Study II. 
 
 
away of the hydrophobic fraction with 6 ml of hexane, the hydrolyzed DHEA fatty acyl 
esters were eluted with 9 ml of hexane: chloroform (1:1, v:v). The samples were further 
purified by use of a DEAE-Ac- ion exchange column (0.5?3 cm) with 4 ml of 70% 
methanol as the elution solvent. After evaporation of the solvent, the dry residue was 
then dissolved in 1 ml of methanol, from which 50 μl was removed for determination of 
recovery. The rest was evaporated to dryness under nitrogen and stored at -20 °C until 
GC–MS and LC–MS/MS analysis. 
The serum samples were processed similarly to adipose tissue (Fig. 3) with some 
modifications. In short, after adding the tritiated recovery standard, 1–3 ml of serum 
was extracted four times with 2.5 ml of diethyl ether. The chromatographic separation 
of DHEA fatty acyl ester from free DHEA, as well as saponification of the DHEA fatty 
acyl ester fraction, were carried out as described for adipose tissue samples. The 
hydrolyzed DHEA fatty acyl ester fraction was further purified by the second 
hydrophobic chromatography (similar to the first separation chromatography, LH-20 
Materials and methods 
34 
column size, 0.5 ? 6 cm). DEAE-Ac- ion exchange chromatography (the last 
chromatography in the adipose method) was not utilized in the analysis of serum. The 
dried DHEA fatty acyl esters and free DHEA fractions were stored at 20°C until GC–MS 
and LC–MS/MS analysis. 
GC–MS and LC–MS/MS analyses 
GC–MS (isotope dilution GC–MS in the selected ion monitoring mode, GC–MS-SIM) 
and LC–MS/MS analyses are explained in detail in the original Study II.  
4.2.7 Assay for esterase activity in adipose tissue (Study III) 
HSL activity was determined by a published method (Tornqvist et al. 1978) with some 
modifications. The experimental details were described in the original Study III. The 
esterified and nonesterified steroid fractions were isolated by Sephadex LH-20 column 
chromatography (Table 4). The samples from the esterase assay for cholesteryl fatty 
acyl esters were subjected to Bligh-Dyer lipid extraction (Bligh & Dyer 1959) and then 
analyzed by TLC (Table 4).  
The preliminary study on hydrolysis of steroid fatty acyl esters was performed in rat 
adipose tissue. The samples were extracted and then analyzed by use of TLC or 
chromatography on LH-20 (Table 4).   
 
Samples Methods Column size or 
references 
Running or eluting solvent 
E2 fatty acyl 
esters/E2 
LH-20  0.5×5 cm Ester fraction: 6 ml hexane:chloroform  
(1:1, v:v); free fraction: 5 ml methanol 
DHEA fatty acyl 
esters/DHEA 
LH-20  0.5×6 cm Ester fraction: 4 ml hexane; free fraction: 
5 ml hexane :chloroform (1:1, v:v)  
E2 fatty acyl 
esters/E2 
TLC  E2 and E2 oleate Hexane: ethyl acetate (70:30, v:v) 
DHEA fatty acyl 
esters/DHEA 
TLC DHEA and DHEA 
oleate 
Hexane: ethyl acetate (70:30, v:v) 
Cholesteryl esters 
/cholesterol 
TLC Cholesterol and 
cholesteryl oleate 
Hexane:diethyl ether:acetic acid: water  
(65:15:1:0.25, v:v:v:v) 
 
Table 4.  Hydrophobic chromatography or TLC used in Study III. 
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4.2.8 Esterification assay of steroids in adipose tissue (Study III) 
The microsomal fractions from human adipose tissue were prepared as described by 
Kanji et al. (1999). The reaction mixture (final volume, 150 μl) had microsomal 
preparation (10 μg protein), [3H]steroid (1.8–3.9×106 dpm; final concentration, ~11 
nmol/l), 10 mmol/l ATP, 1 mmol/l coenzyme A, 5 mmol/l MgCl2, and 2 mmol/l 
dithiothreitol in 0.1 mol/l phosphate buffer. All samples were incubated in duplicate at 
37 °C for 2 h. In some experiments, ACAT inhibitors (rimonabant and PKF 058-035) 
were used to access the role of ACAT in fatty acyl esterification of steroids. Varying 
amounts of rimonabant (in 1 μl of DMSO) or PKF 058-035 (in 1.5 μl of 0.1 mol/l 
phosphate buffer) were preincubated with the microsomal fraction for 30 min at 37 °C. 
Control incubations were done with the microsomal fraction and solvent. The 
incubation mixtures were extracted and analyzed by TLC or Sephadex LH-20 column 
chromatography (Table 4).  
 
4.2.9 Quantification method for E2 fatty acyl esters (Studies III and IV) 
The method for quantifying E2 fatty acyl esters in adipose tissue and serum was 
essentially the same E2 TR-FIA method established earlier in our laboratory (Vihma et 
al. 2001, 2003a, 2004, Badeau M et al. 2007). In addition, concentrations of E2 and E2 
esters in some of the samples (Study III: 12 serum samples and 4 adipose tissue 
samples; Study IV: serum and adipose tissue samples from 10 obese women and 10 
obese men) were also determined by LC–MS/MS analysis.  
Separation and purification of E2 fatty acyl esters and free E2 
In Study III, the fractions of E2 fatty acyl esters and E2 from breast subcutaneous 
adipose tissue and serum were processed by the methods of Badeau M et al. (2007) and 
Vihma et al. (2003a and 2004), respectively. For adipose tissue E2 esters subjected to 
LC–MS/MS analysis, the second column chromatography on Sephadex LH-20 (column 
size, 0.5?5 cm) was repeated for further purification samples.  
In Study IV, to remove excess fat from samples obtained from extremely obese 
subjects, a novel modification was made in the sample purification procedure. In short, 
samples (homogenized subcutaneous and visceral adipose tissue, ~200 mg or serum, 1 
ml) were extracted with 3 ml or 2.5 ml diethyl ether: ethyl acetate (1:1, v:v) four times. 
E2 fatty acyl esters were then separated from free E2 by column chromatography on a 
Sephadex LH-20 (column size, 0.5?5 cm). After eluting the esterified E2 fraction with 
6 ml of hexane:cholorofrom (1:1, v:v), the columns were washed with another 6 ml of 
hexane:cholorofrom (1:1, v:v), and then the nonesterified E2 was eluted with 5 ml 
methanol. The E2 fatty acyl ester was saponified in methanolic KOH, and then was 
extracted twice with 4 ml or 2.5 ml of diethyl ether. The samples were evaporated to 
dryness, dissolved in 1 ml water, and repeatedly extracted as above. After evaporating 
to dryness, the samples were further purified by a second chromatography on Sephadex 
LH-20, in which lipid impurities were washed away with 12 ml hexane:chloroform (1:1, 
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v:v), and hydrolyzed E2 fatty acyl esters were eluted with 5 ml methanol. Both 
hydrolyzed E2 fatty acyl esters and free E2 were stored dry at -20 °C for further TR-FIA 
or LC–MS/MS analysis.  
Control serum samples with addition of low and medium concentrations of E2 17-
stearate, and a pooled male serum sample were included in each assay in Study III and 
IV. A control serum sample with addition of high levels of E2 17-stearate was included 
only in Study III. Before analysis, [3H]-labeled E2-3,17-dioleate was added to 1 ml of the 
above serum samples as an internal standard. After that, they were processed 
identically to the samples.  
Analysis by TR-FIA and LC–MS/MS 
All the samples (except for the adipose tissue E2 and adipose tissue E2 esters subjected 
to LC–MS/MS analysis in Study III) were concentrated two-fold before final 
determination by TR-FIA or LC–MS/MS.  
The dried sample was dissolved in 1 ml methanol, half of which was subjected to 
TR-FIA analysis. After evaporating methanol, the sample was dissolved in the assay 
buffer (0.5% BSA TRIS). The protocol for the commercial TR-FIA reagent set was 
followed, except that the E2 antiserum and europium tracer were 50% more diluted. 
The working range of TR-FIA was 38 to 1840 fmol/mol. The samples whose 
concentrations were out of this TR-FIA working range were reported as being below the 
limit of detection. 
For LC–MS/MS analysis, half of the dried sample was dissolved in methanol (Study 
III) or methanol: water (1:1, v:v, Study IV). The LC–MS/MS analyses were described in 
detail in Study III. The results were corrected by recovery [Study III, individual 
recovery from internal standard added to each sample and Study IV, mean recovery 
(61%) of radiolabeled internal standard added to control samples] and by possible 
dilution factor.  
4.2.10 Quantitative real-time PCR (Study IV) 
Adipose tissue sampling and total RNA and cDNA preparation  
After ~200 mg of frozen adipose tissue sample was homogenized in 1 ml Trizol, the 
total RNA was isolated and purified by the RNeasy Lipid Tissue Mini Kit according to 
the manufacturer's protocols. The isolated RNA was stored at -80°C until further 
analysis. The NanoDrop ND-1000 Spectrophotometer or Agilent 2100 Bioanalyzer 
served to analyze the RNA quality and concentrations. cDNA was translated from 1.0 or 
1.3 μg RNA by use of the SuperScript® VILOTM cDNA Synthesis kit and was stored at -
20°C. Prior to mRNA quantitation, the cDNA samples were transferred into 384-well 
plates as quadruplicates by a Hydra 96 Microdispenser and dried at room temperature.  
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Quantification of mRNA concentrations   
Real-time PCR was performed to quantify mRNA levels of six target genes (LIPE, 
CYP19A1, HSD17B12, STS, HSD17B7, and HSD17B1). The reaction mixture contained 
dried cDNA synthesized from 10 ng of total RNA, 5 μl of 2 × Power SYBR Green PCR 
master mix, and primers to a final volume of 10 μl. The PCR reaction condition was 95 
°C/ 10 min and 45 cycles (95 °C/ 15 s and 57°C/ 1 min), followed by the dissociation 
stage of 95 °C/ 10 s, 57°C/ 15 s and 95 °C/ 15s. The primers used are listed in Study IV. 
The primer pairs were selected by dissociation curves and agarose gel electrophoresis. 
Moreover, the efficiency varied between 90 and 107%. All the samples were run in 
quadruplicate, and the mRNA levels were determined by a comparative Ct method 
using 100% efficiency for calculation. To compensate for differences in cDNA loading, 
the results were further normalized to the geometric mean (Vandesompele et al. 2002) 
of two control genes, importin 8 (IPO8) and lysine (K)-specific demethylase 2B 
(KDM2B). These two control genes, together with ribosomal protein large P0 (RPLP0) 
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were validated by Genorm 
algorithm (Vandesompele et al. 2002) in subcutaneous and visceral fat tissue from 10 
obese females and 10 obese males.   
4.2.11 Statistical analyses 
In Study I, data represent means of multiple experiments, and error bars represent 
standard deviation (SD). The paired t-test was performed with Microsoft Excel 2002 
(Microsoft, Redmond, WA, USA). In Study II to IV, data expressed are the mean (SD) 
or median (range) unless otherwise stated. Nonparametric tests (Mann-Whitney test, 
Wilcoxon signed rank test, and Spearman rank correlation) were performed using SPSS 
Statistics 17.0, 19.0, and 20.0 software (IBM Corporation, Armonk, NY, USA). In all 
studies, statistical significance was assumed if a null hypothesis could be rejected at P= 
0.05.  
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5 RESULTS 
5.1 Role of LAL in cellular metabolism of LDL-associated 
[3H]DHEA fatty acyl esters (Study I) 
5.1.1 Cellular uptake, hydrolysis, and metabolism of LDL-associated 
[3H]DHEA fatty acyl esters 
The LDL-receptor-dependent uptake and metabolism of [3H]DHEA fatty acyl esters 
was studied by incubating LDL-associated [3H]DHEA fatty acyl esters with cultured 
HeLa cells. During incubation, the intracellular radioactivity increased with increasing 
incubation time, and by 6 h of incubation, the cell-associated radioactivity was ~10000 
dpm/mg cellular protein. The intake of [3H]DHEA fatty acyl ester-containing LDL into 
HeLa cells was reduced by ~50% with a 10-fold excess of unlabeled LDL, and was 
reduced ~90% with a 50-fold excess. This effective displacement of label from cells 
implied that the cellular uptake of [3H]DHEA fatty acyl esters was mediated by LDL  
 
  
 
 
 
Figure 4. Identification of [3H]DHEA fatty acyl ester-derived metabolites by 2D-TLC. Autoradiograms 
(II and III) from cells and cell medium, after incubation of LDL-associated [3H]DHEA fatty 
acyl esters with HeLa cells. The rhodamine-stained unlabeled reference steroids were 
visualized by ultraviolet light and their location indicated in I: a) DHEA oleate, b) 5?-adione, 
c) 4-adione, and d) free DHEA. In cells, essentially all the radioactivity comigrated with DHEA 
oleate. In cell medium, the majority comigrated with the 5?-adione standard, whereas smaller 
amounts comigrated with free DHEA and 4-adione. ?, first running; ?, second running. 
Reprinted with publisher's permission from the article that is Study I.  
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receptors or by LDL receptor-related receptors, such as LDL receptor-related protein 1 
(LRP1).  
To explore the metabolic fate of LDL-associated [3H]DHEA fatty acyl esters during  
incubation, we chased labeled steroid products for 48 h. The [3H] label obtained from 
the cellular fraction eluted similarly to the standard DHEA linoleate on Sephadex LH-
20. In contrast, the [3H] label obtained from the cell culture medium fraction contained 
little activity in the ester fraction, the majority eluting in the fractions corresponding to 
unesterified DHEA and other metabolites. This suggested that intracellular hydrolysis 
resulted in secretion of free DHEA and other metabolites into the medium. 
Radiolabeled metabolites were identified by use of one or two-dimensional TLC 
(Fig. 4). Almost all of the radiolabeled steroids in the cellular fraction comigrated with 
the DHEA fatty acyl ester standard (DHEA linoleate or DHEA oleate). Using as 
reference standards the metabolites of DHEA, including 4-adione, 5?-adione, 5?-
androstan-3?-ol-17-one, 5?-androstane-3?,17?-diol, 5?-androstan-17?-ol-3-one, 5?-
androstane-3?,17?-diol, 5?-androstane-3?,17?-diol, testosterone, and 5?-androstan-3?-
ol-17-one, we demonstrated that the radiolabeled steroids from cell culture medium 
comigrated with DHEA oleate, 5?-adione, 4-adione, and free DHEA. Among them, the 
one that migrated at the position of 5?-adione constituted the majority. In addition, 
small amounts of other metabolites remained unidentified. 
5.1.2 Involvement of LAL in [3H]DHEA fatty acyl ester hydrolysis 
LAL hydrolyzes cholesterol fatty acyl esters. To study whether the intracellular 
hydrolysis of [3H]DHEA fatty acyl esters was dependent on LAL, we depleted LAL from 
HeLa cells by small interfering RNA (siRNA) techniques (Elbashir et. al, 2001). After a 
3-day treatment, the loss of a majority of LAL protein from the cells was evident in 
Western blotting (Fig. 5A). The hydrolysis of [3H]cholesteryl fatty acyl esters was 
significantly reduced by LAL-depletion in HeLa cells (Fig. 5B). When monitored in the 
similarly siRNA-treated cells, the hydrolysis of [3H]DHEA fatty acyl esters was, 
however, found to differ from [3H]cholesteryl fatty acyl ester hydrolysis. First, 
significantly more [3H]DHEA fatty acyl esters remained in control siRNA-treated cells 
than did [3H]cholesteryl fatty acyl esters (Fig. 5B). This indicated differential kinetics 
for the hydrolysis of the steroid hormone and cholesteryl fatty acyl esters, with LAL 
siRNA treatment’s having a more modest effect on [3H]DHEA fatty acyl ester- than on 
[3H]cholesteryl fatty acyl ester hydrolysis (Fig. 5B). Together, these data suggest that 
LAL may to a limited extent participate in the hydrolysis of [3H]DHEA fatty acyl esters, 
but other enzymes are likely to be involved.  
To further study the contribution of LAL in the cellular hydrolysis of [3H]DHEA 
fatty acyl esters, hydrolysis of [3H]DHEA fatty acyl esters and [3H]cholesteryl fatty acyl 
esters was compared in human primary fibroblasts from a Wolman disease patient. In 
Wolman disease, the majority of LAL activity is absent (Assmann & Seedorf 2001) and 
no immunoreactive LAL was detected by immunoblotting in the fibroblasts (Fig. 6A). 
Moreover, no hydrolysis of [3H]cholesteryl-esters was observable in these cells (Fig. 
6B). In contrast, a significant hydrolysis of [3H]DHEA fatty acyl esters did take place in 
Wolman fibroblasts, although the extent of its hydrolysis was somewhat smaller than in 
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control cells (Fig. 6B). Taken together, these data indicate that the hydrolysis of 
[3H]DHEA fatty acyl esters is not dependent on a functional LAL, but some minor role 
for LAL in the hydrolysis cannot be excluded.    
 
 
 
   
 
Figure 5. Effect of LAL depletion on [3H]DHEA fatty acyl ester hydrolysis in HeLa cells. A: Western 
blotting of control (ctrl) and LAL siRNA-treated HeLa cell lysates (20 ?g of cellular protein) 
with anti-LAL and anti-actin antibodies. B: Effect of LAL siRNA on the hydrolysis of 
[3H]DHEA fatty acyl esters and [3H]cholesteryl fatty acyl esters in HeLa cells. Control or LAL 
siRNA-transfected cells (open bar or solid bar, respectively) were incubated with LDL-
associated [3H]DHEA- or [3H]cholesteryl fatty acyl esters for 6 h followed by 14–24 h of 
chase. The fraction of steroid remaining as esters was analyzed by TLC for cholesteryl fatty 
acyl esters and by TLC or hydrophobic chromatography for DHEA fatty acyl esters; the 
fraction of steroid esters present at 14 h of chase is shown. Reprinted with publisher's 
permission from the article that is Study I.  
 
 
 
Figure 6. [3H]DHEA fatty acyl ester hydrolysis in Wolman fibroblasts. A: Western blotting of control 
(normal fibroblast) and Wolman fibroblast lysates (20 ?g of cellular protein) with anti-LAL 
and anti-actin antibodies. B: Hydrolysis of [3H]DHEA fatty acyl esters or [3H]cholesteryl fatty 
acyl esters in control (normal fibroblast cells) and Wolman cells. The cells were labeled with 
[3H]DHEA- or [3H]Cholesteryl fatty acyl esters for 8 h, followed by 1 or 2 days (for 
[3H]DHEA fatty acyl esters only) of chase. The fraction of steroid remaining as esters was 
analyzed by TLC. The fraction of steroid esters present immediately after labeling, after 1 day 
of chase, or after 2 days of chase is shown (n= 2 for control and n= 2 to 5 for Wolman cells; 
**, P<0.001). Reprinted with publisher's permission from the article that is Study I. 
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5.2 Concentration of DHEA fatty acyl esters in adipose tissue 
(Study II) 
5.2.1 Quantitative determination of free and esterified DHEA in adipose tissue 
The adipose tissue DHEA quantification method was tested by GC–MS analysis. Two 
ion pairs for DHEA-di-trimethylsilyl (TMSi)/DHEA-d5-diTMSi, m/z 432/437 and m/z 
417/422 were monitored. Since similar results were calculated from these two ion pairs, 
we used the molecular ions (m/z 432 and m/z 437) to present the results. After adding 
9.3 ng of DHEA fatty acyl esters to two samples of 327 mg of pooled adipose tissue, the 
analytical recoveries were 82.5% and 92.5%. For fat tissue with initial sample sizes of 
200 mg and 340 mg, no DHEA fatty acyl esters could be definitely quantified. When 
considering the limit of quantification of GC–MS, dilution factor, and recovery of the 
radiolabeled internal standard, the smallest amount of DHEA that could be detected in 
these sample sizes is about 370 pg. Typical GC–MS-SIM chromatograms of the DHEA 
fatty acyl ester fraction in fat tissue are shown in Figure 7. In order to increase the 
amount of DHEA for analysis, we used a larger fat tissue sample (1200 mg). However, 
the 1200 mg fat sample induced distortion of the internal standard (DHEA-d5), thus 
making quantification impossible.  
 
 
 
Figure 7. GC–MS-SIM chromatograms of DHEA fatty acyl ester fraction in serum (A) and 
adipose tissue (B).            , represents ion chromatogram following the fragment 
432.6 of DHEA-diTMSi;            , represents ion chromatogram following the 
fragment 437.6 of DHEA-d5-diTMSi, internal standard. Reprinted with publisher's 
permission from the article that is Study II. 
 
The concentrations of DHEA fatty acyl esters and free DHEA in 7 individual 
samples and 2 adipose tissue pools are shown in Table 5 (both determined by GC–MS 
and LC–MS/MS). By GC–MS analysis, we found that the amount of DHEA fatty acyl 
esters in adipose tissue was undetectable, whereas free DHEA was measureable. The 
limit of quantification was 3.8 pmol/g or 1.1 ng/g, using a sample size of 340 mg. In five 
premenopausal women, free DHEA concentration in adipose tissue ranged between 
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38.0 and 85.4 pmol/g, and in two postmenopausal women, the range was 86.4 to 
158 pmol/g. Free DHEA concentration was 178 pmol/g in an adipose tissue pool from 
four premenopausal women and 108 pmol/g in another adipose tissue pool from three 
postmenopausal women. Additionally, by using LC–MS/MS determination, no DHEA 
fatty acyl esters were detectable in the fat tissue samples. Whereas DHEA fatty acyl 
esters were below the sensitivity of the LC–MS/MS assay (3.0 pmol/g or 0.9 ng/g, 
using a sample size of 420 mg, signal-to-noise ratio, S/N=10), free DHEA 
concentrations were similar to those obtained by GC–MS analysis.  A strong correlation 
appeared between the adipose tissue free DHEA values obtained by GC–MS and LC–
MS/MS (Spearman's rho = 0.964, P < 0.001, n=7).  
 
Sample  n DHEA fatty acyl esters a Free DHEA a 
GC–MS LC–MS/MS GC–MS LC–MS/MS 
Fat tissue, pre. 5 N.D. b N.D. b 61.3 (38.0–85.4) 57.7 (32.2–101) 
Fat tissue, post. 2 N.D. b N.D. b 122.4 (86.4–158) 131.0 (99.7–162) 
Fat tissue pool, from 4 pre. 1 N.D. b – 178 – 
Fat tissue pool, from 3 post. 1 N.D. b N.D. b 108 – 
Serum, pre. c 7; 12 1.2 (0.7–2.8) N.D. b 13.7 (8.5–27.0) d 12.2 (5.8–23.2) 
Serum, post. c 5; 6 0.6 (0.5–1.4) N.D. b 6.1 (3.8–11.5) d 8.2 (6.0–19.8) 
 
Table 5. DHEA and DHEA fatty acyl ester concentrations in adipose tissue and serum in pre- and 
postmenopausal women. a) Results are expressed as pmol/g or pmol/ml of DHEA, median 
(range). b) N.D. not detectable, defined as below the limit of quantification, based on signal-to-
noise ratio <5:1 in GC–MS and <10:1 in LC–MS/MS. c) Serum data represent determination by 
GC–MS; LC–MS/MS. d) Serum free DHEA, pre- vs. postmenopause, P=0.01 (Mann-Whitney 
test). Reprinted with publisher's permission from the article that is Study II.  
5.2.2 Quantitative determination of free and esterified DHEA in serum 
The concentrations of DHEA fatty acyl esters and free DHEA in serum are in Table 5. 
By GC–MS analysis, concentrations of DHEA fatty acyl esters in serum were lower than 
were those of free DHEA. The median concentration of free DHEA in serum was 13.7 
pmol/ml in premenopausal women, which decreased significantly to 6.1 pmol/ml in 
menopause. However, DHEA fatty acyl esters were slightly, but not significantly lower 
after menopause (1.2 vs. 0.6 pmol/ml, median concentration). In addition, the ratio of 
DHEA fatty acyl esters to free DHEA, calculated as (DHEA fatty acyl esters/free 
DHEA)×100, was slightly higher in postmenopausal women: it was 7.9 (5.4–18.1) in 
pre-, and was 11.4 (9.4–17.8) in postmenopause. But this difference did not reach 
statistical significance. When analyzed by LC–MS/MS, DHEA fatty acyl esters in serum 
were undetectable. The free DHEA concentrations in serum were in the same range as 
with GC–MS determination, which were slightly, but not significantly lower after 
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menopause. Free DHEA concentrations in serum measured by GC–MS and LC–
MS/MS analysis correlated significantly with each other (Spearman's rho = 0.839, 
P = 0.002, n=10).  
5.3 Esterification and De-esterification of E2 in adipose tissue 
(Study III) 
5.3.1 Fatty acyl esterification of E2 in adipose tissue 
Esterification of steroids was explored in a subcutaneous adipose tissue pool from 
reduction mammoplasty specimens from 12 women. In the adipose tissue microsomal 
fraction, [3H]E2 and [3H]DHEA were effectively esterified, but [3H]cholesterol was not 
esterified at all. The esterification rate of [3H]E2 was much higher than was [3H]DHEA: 
12.3 (2.7) vs. 1.9 (0.4) pmol/mg protein/h [mean (SD) of duplicate incubations in four 
separate experiments]. The rate of esterification of [3H]E2 and [3H]DHEA was linear in 
the range of 5 to 50 μg of microsomal protein (P<0.01 for both; Spearman rank 
correlation) (Fig. 8). ACATs catalyze the esterification of cholesterol in the human liver 
and intestine and in cells such as macrophages (Chang et al. 2009). Hence, the 
involvement of ACAT in the esterification of steroids was studied by use of two specific 
inhibitors. PKF 058-035 (4.3 μM), an ACAT1 inhibitor (Ross et al. 1984), had no effect 
on the fatty acyl esterification of [3H]E2 or [3H]DHEA. In contrast, 100 μM of 
rimonabant (an inhibitor of both ACAT1 and ACAT2) (Netherland & Thewke 2010) 
partially inhibited the formation of fatty acyl esters of [3H]E2 (mean inhibition was 
39%; range, 28–47%). A higher concentration of rimonabant (500 and 1000 μM) 
further reduced the synthesis of fatty acyl esters of [3H]E2 (by 61% and 69%, 
respectively). However, it had no significant effect on the esterification of [3H]DHEA.  
 
 
 
Figure 8. Correlation of fatty acyl esterification rate of E2, DHEA, and cholesterol with human adipose 
tissue microsomal protein amount. Incubations of [3H]steroids with adipose tissue 
microsomal fraction were carried out at 37 °C for 2 h. The [3H]steroid fatty acyl esters formed 
were analyzed by TLC. Data expressed are the mean of duplicate incubations. Reprinted with 
publisher's permission from the article that is Study III.  
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5.3.2 Hydrolysis of E2 fatty acyl esters in adipose tissue 
The preliminary study of the hydrolysis of steroid esters was performed in rat adipose 
tissue. We observed that [3H]cholesterol oleate was more rapidly hydrolyzed than was 
[3H]E2 17-monooleate, at rates of 0.63 vs. 0.34 pmol/mg protein/h respectively (means 
of two parallel experiments). After denaturation of the enzyme in the adipose tissue 
infranatant by incubation at 80 °C for 30 min, no hydrolysis of steroid esters occurred. 
Phenylmethylsulfonyl fluoride (PMSF, a known serine esterase inhibitor) at a 
concentration of 100 μM almost totally inhibited the hydrolysis of [3H]cholesterol 
oleate as well as [3H]DHEA fatty acyl esters. With the same concentration of PMSF, 
however, only 34% of the [3H]E2 17-monooleate hydrolysis was inhibited. 
In human adipose tissue, these hydrolytic reactions were linear in the range of 80 to 
515 μg infranatant protein and at 15 to 120 min of incubation time (P<0.01 for all). 
With each concentration of infranatant protein, the hydrolysis of [3H]E2 17-monooleate 
was constantly slower than was that for the other two steroid esters. To obtain a higher 
hydrolysis rate, we chose the 2-h incubation time for further experiments. In addition, 
during the 2-h incubation, the hydrolysis rate of steroid esters did not increase with 
increasing substrate amount (concentration in the range of 0.5–4.6 nmol/l for [3H]E2 
fatty acyl esters, 0.7–7.9 nmol/l for [3H]cholesterol oleate, and 0.4–3.6 nmol/l for 
[3H]DHEA fatty acyl esters). This indicated possible saturation of the reaction.  
The steroid fatty acyl ester-hydrolyzing activity in subcutaneous adipose tissue in 
women (for [3H]E2 fatty acyl esters and [3H]cholesterol oleate n=12, for [3H]DHEA fatty 
acyl esters n=16) is shown in Figure 9A. In human adipose tissue, in line with 
experiments with the rat, [3H]E2 fatty acyl esters were hydrolyzed at a significantly 
lower rate than were [3H]cholesterol oleate and [3H]DHEA fatty acyl esters (Fig. 9A). A 
positive correlation appeared between the hydrolysis of [3H]DHEA fatty acyl esters and 
[3H]cholesterol oleate, similar in breast quadrants 1 and 2 (n=12, Spearman rho=0.909, 
P<0.001, for both). However, the hydrolysis of [3H]E2 fatty acyl esters showed no 
correlation with the hydrolysis of [3H]DHEA fatty acyl esters or [3H]cholesterol oleate. 
The hydrolysis rates did not differ between pre- and postmenopausal women (Fig. 9A).  
To assess the potential role of HSL in steroid ester hydrolysis in adipose tissue required 
a specific HSL inhibitor 76-0079 (Schweiger et al. 2006, Alsted et al. 2009). In the 
presence of this HSL inhibitor (25 ?M), the hydrolysis of [3H]E2 fatty acyl esters was 
partially inhibited by a mean of 35% (range of inhibition, 33–51%, Fig. 9B). No 
increasing inhibition effect occurred with higher concentrations of the HSL inhibitor 
(Fig. 9B). In contrast to [3H]E2 esters, the hydrolysis of fatty acyl esters of 
[3H]cholesterol and [3H]DHEA was already markedly inhibited at 5 μM inhibitor 
concentration and almost completely inhibited at 25 μM of the HSL inhibitor (Fig. 9B). 
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Figure 9. Hydrolysis of steroid fatty acyl esters in human breast subcutaneous adipose tissue. A.  
Hydrolysis of [3H]labeled steroid esters in subcutaneous adipose tissue in 16 (DHEA fatty 
acyl esters) or 12 women (E2 fatty acyl esters and cholesterol oleate) undergoing reduction 
mammoplasty. Q 1, quadrant 1; Q 2, quadrant 2. B. Inhibition of HSL activity and hydrolysis 
of steroid esters by human adipose tissue. Incubation was performed for 2 h at 37 ?C. The 
hydrolysis of steroid esters by adipose tissue infranatant is expressed as: (hydrolysis at 
different concentrations of the HSL inhibitor/hydrolysis with the added solvent only) × 100%. 
Data points are the mean (range) of duplicate incubations (E2 fatty acyl esters, 2 to 3 separate 
experiments; DHEA fatty acyl esters, 1 to 2 separate experiments; cholesterol oleate, one 
experiment). Reprinted with publisher's permission from the article that is Study III.     
5.4 E2 fatty acyl esters in human breast subctaneous adipose 
tissue (Study III) 
The concentrations of E2 and E2 fatty acyl esters in breast adipose tissue and serum in 
12 women undergoing reduction mammoplasty surgery are shown in Table 6. None of 
the 12 subjects used systemic (oral or transdermal) estrogen regimens at the time of the 
operation. Their menopausal status was confirmed by serum FSH concentration 
(reference value for FSH in postmenopausal women, 26 to 135 IU/l; 
immunofluorometric method, HUSLAB, Helsinki University Central Hospital). The 
interassay coefficients of variation (CV) for control serum samples containing three 
concentrations of E2 17-stearate (corresponding to free E2 concentrations of 110, 257, 
and 598 pmol/l) were 23, 12, and 3% in adipose tissue analysis, and 21, 11, and 10% in 
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serum analysis. Serum E2 determination in premenopausal women by TR-FIA 
correlated perfectly with those achieved by the reference method LC–MS/MS 
(Spearman rho=1.00, P<0.01, n=8). However, postmenopausal serum E2 and E2 fatty 
acyl ester concentrations measured by immunoassay were higher than those obtained 
by LC–MS/MS (Table 6).         
In all subjects, the adipose tissue estrogen levels were higher than the serum levels. 
The mean E2 concentration in subcutaneous adipose tissue from two quadrants of the 
breast in premenopausal women correlated positively with serum E2 (Spearman 
rho=0.714, P=0.047, n=8). In premenopausal subcutaneous adipose tissue, the 
concentration of E2 fatty acyl esters was slightly, but not significantly higher than was 
nonesterified E2 (Table 6). In postmenopausal women, E2 fatty acyl ester 
concentrations in adipose tissue were comparable to those of premenopausal women; 
however, no nonesterified E2 in adipose tissue was detectable (Table 6). It appeared 
that in postmenopausal subcutaneous adipose tissue, a major part of the E2 was in the 
fatty acyl esterified form. 
 
 
 Premenopausal (n=8) Postmenopausal (n=4) 
Age (yr) 43 (34–53) 62 (53–68) 
BMI (kg/m2) 26 (24–29) 29 (26–29) 
E2 fatty acyl esters (fmol/g or pmol/l) a  
Fat tissue, quadrant 1 987 (589–1777) 1056 (714–1341) 
Fat tissue, quadrant 2 742 (552–2953) 908 (815–1099) 
Serum 109 (80–178); 27 (17–42) 73 (55–117); 23 (<15–27) c  
E2  (fmol/g or pmol/l) b   
Fat tissue, quadrant 1  798 (238–1544) ND d 
Fat tissue, quadrant 2 722 (192–2118) (n=7) ND d 
Serum 327 (76–820) e; 421 (67–1135) 36 (33–56); 10 (8.0–16) 
 
Table 6. Age, BMI, and E2 and E2 fatty acyl ester concentrations in breast subcutaneous adipose tissue 
and in serum of pre- and postmenopausal women by TR-FIA or serum by LC–MS/MS. 
Results are expressed as fmol/g or pmol/l of E2, median (range). Serum data represent analysis 
by TR-FIA; LC–MS/MS. a) E2 fatty acyl esters in quadrant 1 and 2, Spearman rho=0.776, 
P=0.003, n=12. b) Premenopausal E2 in quadrants 1 and 2, Spearman rho=0.881, P=0.004, 
n=7. c) The concentration of fatty acyl esters in one subject was below the detection limit of LC–
MS/MS analysis (15 pmol/l). d) N.D., undetectable; the detection limit of E2 was 190 fmol/g in 
0.2 g of tissue. e) P=0.017, premenopausal tissue E2 vs. serum E2; Wilcoxon signed rank test. 
Reprinted with publisher's permission from the article that is Study III.      
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5.5 E2 fatty acyl esters in obese men and women  (Study IV) 
5.5.1 Assay characteristics of the modified E2 fatty acyl ester analytical 
method (TR-FIA) 
 
  
  
 
 
 
Figure 10.  Serum and adipose tissue E2 fatty acyl ester analysis in obese subjects by use of TR-FIA 
and LC–MS/MS. A and B: Subcutaneous and visceral adipose tissue, below the limit of 
quantification by LC–MS/MS in two and five samples (not shown), respectively. C and D: 
Serum. E: Three control samples (pooled male sera, and E2 17-stearate-containing low and 
medium control serum), analyzed in four separate assays (n=12).  Reprinted with publisher's 
permission from the article that is Study IV.     
 
When adipose tissue (~200 mg) was spiked with E2 17-stearate (corresponding to 250 
pg of E2), the analytical recovery was good (96%, mean, range of 88% to 108%; n=4). In 
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all of 13 assays, the interassay CV for pooled male sera and two control serum samples 
with additional E2 17-stearate (corresponding to E2 concentrations of 110 and 257 
pmol/l) was 20%, 13%, and 9%, respectively.  
Correlation between TR-FIA and LC–MS/MS in determination of E2 and E2 fatty 
acyl esters in adipose tissue was significantly positive (Fig. 10). In addition, the 
repeated analysis of E2 esters in control serum samples correlated well between the two 
methods (Fig. 10). In contrast, serum E2 fatty acyl ester concentrations in obese 
subjects measured by both TR-FIA and LC–MS/MS did not correlate significantly with 
each other, whereas the median values observed were similar (Fig. 10). This might be 
explained by the higher imprecision of TR-FIA when relatively low levels of E2 fatty acyl 
esters were analyzed.  
5.5.2 E2 and E2 fatty acyl esters in obese men and women 
The concentrations of E2 and E2 fatty acyl esters in adipose tissue and serum in 22 
obese women, 14 obese men, and 10 control women are shown in Table 7. In all groups, 
the median concentration of E2 in adipose tissue was higher than that in serum. In 
obese women, concentrations of E2 in subcutaneous adipose tissue and serum were 
higher than in obese men. While the E2 concentrations in subcutaneous fat and serum 
did not differ, control women had a higher median level of E2 in visceral fat than did  
 
 Obese men 
(n=14) 
Obese women 
(n=21) 
  Control women 
(n=8) 
E2 fatty acyl esters a 
Subc. fat, pmol/kg 251 (45-804) b 255 (57-1001) e, ** 148 (121-277) h, * 
Visc. fat, pmol/kg 262 (44-562) c 216 (52-1803) (n=19) f, * 212 (122-328) i, * 
Serum, pmol/l 79 (21-130) d, ** 51 (16-156) (n=20) g, ** 52 (35-85) * 
E2 
Subc. fat, pmol/kg 262 (183-421) 422 (117-1514) † 609 (175-1673) † 
Visc. fat, pmol/kg 267 (143-361) 398 (102-1649) (n=19) 586 (203-1156) †† 
Serum, pmol/l 102 (55-138) k 245 (48-954) (n=20) †† 256 (57-625) †† 
 
Table 7. Concentrations of E2 fatty acyl esters and E2 in adipose tissue and serum in obese men and 
women, and in control women. a) Concentration expressed as pmol/kg or pmol/l of E2.  The 
concentration of E2 fatty acyl esters was below the limit of quantification (151 pmol/kg in 
adipose tissue or 30 pmol/l in serum) in the following number of subjects: b) n=5; c) n=4; d) 
n=2; e) n=5; f) n=10; g) n=8; h) n=5; i) n=2. *) P<0.05, **) P<0.01; E2 fatty acyl esters vs. E2 
(Wilcoxon signed ranks test). †) P<0.05, ††) P<0.01; E2  in women vs. E2 in men (Mann-Whitney 
U test). k) Reference value for serum E2 in men, 0-130 pmol/l, immunofluorometric method, 
HUSLAB, Helsinki University Central Hospital. Reprinted with publisher's permission from the 
article that is Study IV.  
 49 
 
Figure 11. Correlation of E2 fatty acyl ester concentrations in visceral adipose tissue with circulating 
E2 fatty acyl esters and E2 levels in obese men or women. A. E2 fatty acyl esters in visceral 
adipose tissue vs. that in serum in obese men (n=14). B. E2 fatty acyl esters in visceral 
adipose tissue vs. serum E2 in obese men (n=14). C. E2 fatty acyl esters in visceral adipose 
tissue vs. that in serum in obese women (n=19). One outlier with E2 fatty acyl ester 
concentration in visceral adipose tissue as 1803 fmol/g has been excluded from figure C. 
Reprinted with publisher's permission from the article that is Study IV.  
 
obese women. In both genders, the levels of E2 in subcutaneous fat showed a positive 
correlation with those in visceral fat (P<0.01). In obese women and men, no significant 
correlation emerged between serum and adipose tissue E2 levels. In control women, 
however, serum E2 correlated positively with E2 in visceral adipose tissue (Spearman 
rho=0.905, P=0.002, n=8).   
Approximately two-thirds of the obese men and women had quantifiable amounts 
of E2 fatty acyl ester in their adipose tissue (Table 7). In all subjects, the E2 fatty acyl 
ester concentrations in subcutaneous and visceral adipose tissue correlated 
significantly with each other (Spearman rho=0.763, P=0.002, n=14; Spearman 
rho=0.819, P<0.01, n=19; Spearman rho=0.714, P=0.047, n=8; respectively), but the 
levels were similar in both tissues. E2 fatty acyl ester concentrations in adipose tissue in 
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obese men were in the same range as those in obese women. Differing from obese men, 
obese and control women had significantly lower levels of E2 fatty acyl esters in 
subcutaneous and visceral adipose tissue compared to E2 levels. In obese men, serum E2 
fatty acyl esters and E2 correlated positively with each other (Spearman rho=0.613, 
P=0.02, n=14), and both of them also correlated positively with visceral adipose tissue 
E2 fatty acyl ester concentration (Fig. 11A and 11B). In obese women, adipose tissue E2 
fatty acyl esters were positively related to serum E2 fatty acyl esters (Fig. 11C), but not to 
serum E2 level.  
5.6 Gene expression of enzymes regulating estrogen in adipose 
tissue (Study IV) 
Gene Adipose tissue and  
fold difference  
Obese men 
(n=14) 
Obese women 
(n=22) 
Control women 
(n=10) 
CYP19A1 Subc. fat 0.312 (0.157) 0.393 (0.263) 0.281 (0.240) 
Visceral fat a 0.071 (0.086) 0.041 (0.030) 0.074 (0.038) 
Fold difference 5.9** 9.8**, # 4.1*, # 
STS Subc. fat b 0.245 (0.082) 0.565 (0.210) 0.423 (0.166) 
Visceral fat c 0.166 (0.090) 0.233 (0.085) 0.204 (0.108) 
Fold difference 1.5* 2.4** 2.7* 
HSD17B1 Subc. fat d 0.141 (0.074) 0.338 (0.204) 0.292 (0.188) 
Visceral fat e 0.325 (0.155) 0.381 (0.188) 0.239 (0.196) 
Fold difference  0.5** 0.9 1.1 
HSD17B7 Subc. fat f 0.125 (0.057) 0.215 (0.118) 0.257 (0.126) 
Visceral fat  0.144 (0.110) 0.192 (0.173) 0.295 (0.284) 
Fold difference 0.9 1.4* 1.1 
HSD17B12 Subc. fat g 0.253 (0.106) 0.427 (0.211) 0.563 (0.224) 
Visceral fat  0.305 (0.227) 0.370 (0.172) 0.490 (0.317) 
Fold difference 0.9 1.2 1.5 
LIPE Subc. fat h 0.363 (0.086) 0.545 (0.187) 0.480 (0.272) 
Visceral fat  0.262 (0.151) 0.279 (0.127) 0.264 (0.204) 
Fold difference  1.5* 2.4** 2.7* 
 
Table 8.  Gene expression in obese men and women and in control women. Data on relative mRNA 
levels are presented as mean (SD), and data on fold difference (subcutaneous fat vs. visceral 
fat) as median. Obese women vs. control women: a) P=0.025, e) P=0.016; Obese men vs. 
obese women: b) P<0.001, c) P=0.030,  d) P<0.001, f) P=0.011, g) P=0.005, h) P=0.002. 
Comparison of gene expression levels in subcutaneous fat vs. visceral fat: *) P<0.05, **) 
P<0.01,  #) P=0.011, fold difference in obese women vs. control women (Mann-Whitney U 
test). Reprinted with publisher's permission from the article that is Study IV.      
 51 
 
The relative mRNA expression levels of certain key enzymes regulating estrogen 
metabolism, such as LIPE, CYP19A1, STS, HSD17B1, HSD17B7, and HSD17B12 in 
subcutaneous and visceral fat in all three groups, are shown in Table 8. The mRNA 
expression of HSD17B12 correlated positively with expression levels of CYP19A1, STS, 
and HSD17B7 in both sexes (P<0.01 for all). It had no significant correlation with 
HSD17B1. In all subjects, compared to visceral fat, subcutaneous adipose tissue had 
higher expression levels of CYP19A1, STS, and LIPE (Table 8). The difference between 
subcutaneous adipose tissue and visceral adipose tissue regarding CYP19A1 mRNA 
expression was significantly higher in obese women than in control women (Table 8). 
In control women, but not in the severely obese subjects, CYP19A1 mRNA expression in 
subcutaneous adipose tissue was positively correlated with BMI (Spearman rho=0.782, 
P=0.008, n=10). In visceral adipose tissue in obese women, CYP19A1 expression level 
was lower, but that of HSD17B1 was higher than in control women (P=0.025 and 
P=0.016, respectively). Compared to obese men, obese women had significantly higher 
STS expression in their subcutaneous and visceral fat and higher HSD17B mRNA levels 
in subcutaneous adipose tissue (P<0.05 for all).    
In subcutaneous adipose tissue in obese men, E2 concentration was positively 
correlated with STS and LIPE mRNA expression levels (Spearman rho=0.574, P=0.032 
and Spearman rho=0.793, P=0.001, n=14, respectively), whereas serum E2 
concentration was related positively to the HSD17B1 mRNA expression in 
subcutaneous adipose tissue (Spearman rho=0.534, P=0.049). Furthermore, serum E2 
concentrations in obese men were inversely associated with mRNA expression level of 
CYP19A1, STS, HSD17B7, and HSD17B12 in visceral adipose tissue (Spearman rho=-
0.574, P=0.032; Spearman rho=-0.626, P=0.017; Spearman rho=-0.684, P=0.007; and 
Spearman rho=-0.675, P=0.008, respectively) and HSD17B7 in subcutaneous adipose 
tissue (Spearman rho=-0.604, P=0.022). In obese women, a negative correlation 
existed between serum E2 and HSD17B1 mRNA expression in subcutaneous adipose 
tissue (Spearman rho=-0.493, P=0.027, n=20). In contrast, the levels of E2 fatty acyl 
esters in adipose tissue or serum were not significantly correlated with mRNA 
expression of any of the genes studied. 
 
 
      
Discussion 
52 
6 DISCUSSION 
6.1 Enzymes regulating hydrolysis of DHEA and E2 fatty acyl 
esters (Studies I and III) 
6.1.1 Uptake and metabolism of LDL-associated [3H]DHEA fatty acyl esters  
Investigation of the uptake of [3H]DHEA fatty acyl esters by HeLa cells and the 
metabolic fate of [3H]DHEA fatty acyl esters inside these cells demonstrated that LDL-
associated [3H]DHEA fatty acyl esters entered HeLa cells via LDL receptors or LDL 
receptor-related receptors such as LRP1. Free DHEA, intracellularly hydrolyzed from 
[3H]DHEA fatty acyl esters, was further converted into its metabolites, [3H]5?-adione 
and [3H]4-adione, which were secreted out of cells.  
Lipoproteins are important vehicles for transporting steroid fatty acyl esters in the 
circulation (Roy & Bélanger 1989a, Lavallée et al. 1996a, Helisten et al. 2001). After 
formation in the HDL fraction in circulation, DHEA fatty acyl esters can be transferred 
into the LDL and VLDL fraction by a CETP-independent pathway (Provost et al. 1997). 
In blood, the majority of DHEA fatty acyl esters occur in lipoprotein fractions, 46% in 
LDL and 37% in HDL (Roy & Bélanger 1989a). The lipoprotein receptor-dependent 
internalization of steroid fatty acyl esters has been described for pregnenolone, DHEA 
and E2 fatty acyl esters (Roy & Bélanger 1991, 1993, Provencher et al. 1992, Badeau RM 
et al. 2007, Paatela et al. 2011). In agreement with earlier studies, we showed that the 
incorporation of LDL-carrying tritium-labeled DHEA fatty acyl esters into HeLa cells 
was significantly reduced by an excess of unlabeled LDL. Our data implied that this 
uptake was mediated by LDL receptors or LDL receptor-related receptors. However, 
LDL receptor belongs to a family of structurally and functionally related cell surface 
receptors, most of which can bind and internalize LDL (Hussain et al. 1999, Nykjaer & 
Willnow 2002, Gent & Braakman 2004). Therefore, although LDL receptors are 
abundant in HeLa cells, the possibility that additional members of the LDL receptor 
family might participate in the internalization cannot be excluded. In addition, in LDL 
competition experiments, a small residual amount (~10%) of tritium label was 
observable in the cellular fractions in the presence of excess unlabelled LDL indicating 
a relatively minor LDL receptor independent uptake.  
The circulating steroid fatty acyl esters incorporated into lipoproteins can serve as 
storage forms for active steroids after their entry into target cells. For example, in 
porcine granulosa cells and in guinea pig adrenal cells, HDL- and LDL-associated 
pregnenolone fatty acyl esters can generate free pregnenolone, progesterone, and 
various metabolites of progesterone (Roy & Bélanger 1991, Provencher et al. 1992). In 
addition, ZR-75–1 breast cancer cells can convert LDL-associated DHEA fatty acyl 
esters to free DHEA and androst-5-ene-3?,17?-diol  (Roy & Bélanger 1993). In 
agreement with these earlier studies, the present study found that free [3H]DHEA and 
two of its metabolites, [3H]4-adione and [3H]5?-adione, were produced intracellularly 
from LDL-associated [3H]DHEA fatty acyl esters. DHEA, as a hormone precursor 
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hormone, can be metabolized to androgenic and estrogenic steroids in peripheral 
tissues (Labrie et al. 2005). The conversion of [3H]DHEA to [3H]4-adione and [3H]5?-
adione in HeLa cells suggested the existence of necessary steroidogenic enzyme 
activities. In contrast to E2 fatty acyl esters that display a long plasma half-life in men 
and animals  (Janocko et al. 1984, Larner & Hochberg 1985), DHEA fatty acyl esters are 
reported to have a very short half-life in plasma when injected into guinea pigs 
(Bélanger et al. 1992). What is unknown is whether the rapid clearance of DHEA fatty 
acyl esters from blood has any metabolic relevance. Paatela et al. (2011) have, however, 
demonstrated that HDL-associated DHEA fatty acyl esters enhance vasodilation in 
vitro, but this is not likely to be attributable to its rapid hydrolysis by the vascular 
endothelium.  
6.1.2 The hydrolytic enzymes for DHEA and E2 fatty acyl esters 
Lysosomal acid lipase, LAL, participated to some extent in the hydrolysis of [3H]DHEA 
fatty acyl esters in cultured cells. Whereas HSL plays a major role in the hydrolysis of 
[3H]DHEA and [3H]cholesteryl esters, the hydrolysis of [3H]E2 fatty acyl esters in 
subcutaneous adipose tissue from human breast was less dependent on the activity of 
HSL. 
Steroid fatty acyl esters are inactive hormones and need to be hydrolyzed to free 
steroid to become active (Janocko et al. 1984). Thus, the relevant enzymes are the key 
factors regulating the amounts of active steroids in target tissues. LAL is considered to 
be responsible for the hydrolysis of cholesteryl esters in lysosomal fractions (Ameis et 
al. 1994). Because DHEA is structurally similar to cholesterol, it is therefore reasonable 
to assume that its esters can also be hydrolyzed by LAL. However, hydrolysis of 
[3H]DHEA fatty acyl esters was quite different from the hydrolysis of [3H]cholesteryl 
esters in HeLa cells and in LAL-deficient human fibroblasts. This lack of LAL activity 
reduced, to a small extent, the hydrolysis of [3H]DHEA fatty acyl esters. These data 
suggest that LAL played a partial role in the hydrolysis of [3H]DHEA fatty acyl esters, 
and that other unidentified esterase(s) are also involved.  
HSL is responsible for the hydrolysis of cholesteryl esters and triglyceride in adipose 
tissue. By means of a specific inhibitor of HSL (Schweiger et al. 2006, Alsted et al. 
2009), the hydrolysis of [3H]DHEA fatty acyl esters and [3H]cholesteryl esters was 
almost totally blocked. Moreover, in the breast subcutaneous adipose tissue, the 
hydrolysis of [3H]DHEA fatty acyl esters correlated positively with the hydrolysis of 
[3H]cholesteryl esters. This suggests that DHEA and cholesteryl esters are hydrolyzed 
by the same enzyme, which was most likely HSL. However, the specific HSL inhibitor 
reduced the hydrolysis of [3H]E2 fatty acyl esters by only 30 to 50%, which implied that 
the HSL was only partly responsible for the hydrolysis.  
6.2 DHEA fatty acyl esters in adipose tissue (Study II) 
The present thesis project shows that the amount of DHEA fatty acyl esters in adipose 
tissue was not quantifiable in pre-and postmenopausal women, whereas the free DHEA 
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concentrations were 4 to 10 times as high as those in serum. In serum, DHEA fatty acyl 
ester concentrations were 0.5 to 2.8 pmol/ml in pre- and postmenopausal women as 
quantified by GC–MS. In addition, the mean proportion of DHEA fatty acyl esters to 
total DHEA was 9.7%. In both adipose tissue and serum, free DHEA values obtained 
from GC–MS and LC–MS/MS analysis significantly correlated with each other.  
We and others have demonstrated that E2 accumulates in adipose tissue as its fatty 
acyl ester form (Larner et al. 1992, Badeau M et al. 2007). In contrast, the present data 
suggest that only free DHEA is detectable in adipose tissue. In humans and other 
primates, de novo synthesis of steroids in adipose tissue is unlikely. However, DHEA 
and DHEA-sulphate (quantitatively the most important hormone precursor), secreted 
by adrenal glands and postmenopausal ovaries, can be converted to active androgen 
and estrogen by enzymes expressed in adipose tissue (Mohamed-Ali et al. 1998). In 
addition, DHEA-sulfate is selectively taken up by adipose tissue cells and then 
desulfated in situ producing further conversion to other steroids (Valle et al. 2006). 
Because DHEA fatty acyl esters were not quantifiable in our human adipose tissue, it 
appears that either DHEA is not effectively esterified, or DHEA fatty acyl esters formed 
or taken up from the circulation are hydrolyzed into free DHEA immediatedly. 
Alternatively, after local formation or uptake from the circulation, DHEA fatty acyl 
esters may be hydrolyzed into free DHEA immediately. In line with this, our study in 
human subcutaneous adipose tissue showed that fatty acyl esterified DHEA was 
hydrolyzed more rapidly than E2 esters, and that free DHEA was esterified more slowly 
than was E2. In addition, the enzymatic hydrolysis differed between DHEA and E2 
esters, since the latter was less dependent on HSL. As a hormone precursor, it is natural 
for DHEA to exist in unconjugated form in adipose tissue, which makes it possible to be 
converted to active steroid when needed.   
The serum free DHEA concentrations presented here are comparable to levels 
obtained by GC–MS analysis by Labrie et al. (2006). Serum DHEA fatty acyl ester 
levels were, however, much lower than the levels achieved in immunoassay studies 
(Bélanger et al. 1994, Labrie et al. 1997b, Couillard et al. 2000). It is well recognized 
that immunoassay-based methods, compared to mass spectrometric methods, tend to 
give higher values especially when low concentrations of samples are analyzed. This 
may be attributable to cross-reaction or matrix interference effects or other factors 
(Hsing et al. 2007, McNamara et al. 2010). In contrast to earlier studies that showed 
the proportion of DHEA fatty acyl esters to total DHEA increasing with ageing 
(Bélanger et al. 1994, Labrie et al. 1997b, Couillard et al. 2000), the current study 
shows that between pre- and postmenopausal women, the proportion of DHEA fatty 
acyl esters of total DHEA did not significantly differ. This might be explained by the 
methodological difference and our relatively small samples size. In addition, the high 
interindividual variation among free DHEA concentrations in postmenopausal women 
may cause difficulties for the comparison (Labrie et al. 2011). What was unexpected was 
that DHEA fatty acyl esters in serum could not be quantified by LC–MS/MS analysis. 
Although LC–MS/MS is very specific and accurate and thus is a superior tool for most 
substances, in this study GC–MS proved to be more sensitive, as has been suggested for 
quantification of novel steroid metabolites at levels near their detection limit (Stanczyk 
& Clarke 2010). This is partly due to use of a long capillary column and a slow 
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temperature program whereby GC analysis separates substances with very closely 
related structures with a better resolution than does LC (Krone et al. 2010).  
Apart from adipose tissue, DHEA fatty acyl esters in the adrenals of several animals 
and man (Bélanger et al. 1990), as well as in rat brain (Liere et al. 2004, Jo et al. 1989) 
have been determined by immunoassay or GC–MS analysis. In line with the E2 fatty 
acyl ester method, the novel DHEA fatty acyl ester method requires extensive 
purification of the DHEA fatty acyl ester fraction by use of three-column 
chromatographic steps to abolish interference with contaminating substances. Unlike 
in the serum method, however, it is impossible to increase fat sample size despite 
intensive pre-purification prior to mass spectrometric analysis. The complexity of the 
DHEA fatty acyl ester method restricted the number of samples analyzed.  
6.3 Esterification and de-esterification of E2 in adipose tissue 
(Study III) 
As studied in 12 women undergoing reduction mammoplasty, the hydrolysis rate of 
[3H]E2 fatty acyl esters in breast subcutaneous adipose tissue was much slower than 
was that of DHEA fatty acyl esters and [3H]cholesteryl esters. In agreement with the 
present findings, earlier studies in humans and experimental animals (Hershcopf et al. 
1985, Larner & Hochberg 1985) indicated that the esterase activity against E2 fatty acyl 
esters is relatively low. Unlike DHEA fatty acyl esters and cholesteryl oleate, the fatty 
acyl group was located at the carbon-17 position of E2 (Schatz & Hochberg 1981, Martyn 
et al. 1988). The poor accessibility for esterases due to steric hindrance at carbon-17 
causes the delay in releasing the long fatty acyl chain. 
To the best of our knowledge, this is the first study to show the fatty acyl 
esterification of E2 in human subcutaneous adipose tissue. Kanji et al. (1999) have 
showed that E2 is more rapidly esterified in human omental (visceral) adipose tissue 
than in placenta suggesting the possibility that adipose tissue may be an active site of E2 
fatty acyl esterification. In blood and ovarian follicular fluid, the formation of steroid 
fatty acyl ester and cholesteryl ester is catalyzed by the same enzyme, LCAT (Roy & 
Belanger 1989a, Lavallée et al. 1996b, Höckerstedt et al. 2002, 2004). Acyl coenzyme A: 
acyltransferanse activity (ACAT) has been detectable in the microsomal fraction in 
several tissues (Lee & Adams 1987, Adams et al. 1988, Martyn et al. 1988, Paris & Rao 
1989). In rat liver microsomes, it seems that the fatty acyl esterification of E2 and 
DHEA is independent of ACAT activity (Pahuja & Hochberg 1995). Here, in adipose 
tissue microsomes derived from human breast, one of the two ACAT inhibitors we used 
could, at a high concentration, reduce the esterification of E2 but not that of DHEA. 
This could indicate a nonspecific effect; the role of ACAT in the synthesis of E2 fatty acyl 
esters therefore remains to be verified. Compared to E2, the esterification rate of DHEA 
was much slower, and inversely, the hydrolysis rate of DHEA fatty acyl esters was much 
higher than that of E2 esters. This finding is in accordance with our observation that in 
human fat tissues, no amount of DHEA fatty acyl esters was detectable. Together, these 
results indicate that in human adipose tissue, the hydrolysis of DHEA fatty acyl esters 
may be more active than the esterification of DHEA with fatty acids—thus making 
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unconjugated DHEA ready available. In addition, almost no esterification of cholesterol 
took place in adipose tissue. Similarly, the levels of cholesteryl esters in adipose tissue 
have been reported as low and adipose tissue contains relatively high levels of free 
cholesterol (Kovanen & Nikkila 1976, Krause & Hartman 1984, Chung et al. 2011).  
6.4 E2 fatty acyl esters in adipose tissue (Studies III and IV) 
6.4.1 The analytical method for E2 fatty acyl ester determination in adipose 
tissue 
It is methodologically complicated to quantify fatty acyl esterified E2, as well as DHEA 
and other steroids in adipose tissue, which may limit such studies. The major challenge 
is how to successfully isolate the lipophilic E2 fatty acyl esters from other abundant 
steroid conjugates and hydrophobic substances (such as triglycerides and cholesterol) 
(Vihma & Tikkanen 2011). The presence of these compounds may disturb the final 
quantitative assay. The quantitative immunologic E2 fatty acyl ester method used in the 
present study was essentially the same that we established earlier (Badeau M et al. 
2007). When we analyzed the subcutaneous adipose tissue samples from human breast, 
we added an extra chromatography purification step for the hydrolyzed E2 ester 
fraction of the samples subjected to LC–MS/MS analysis. This step was, however, not 
applied to those samples prepared only for TR-FIA analysis. Thus it was possible that, 
for the latter samples, some lipophilic contaminants might have caused overestimation 
of E2 fatty acyl ester concentrations. Moreover, when analyzing the adipose tissue 
obtained from morbidly obese individuals, a novel modification of the chromatographic 
step was made to remove excessive fat from both free E2 and hydrolyzed E2 ester 
fractions. This modification leads to accurate determination of E2 and E2 fatty acyl 
esters in adipose tissue by immunoassay, as confirmed by LC–MS/MS.    
6.4.2 E2 fatty acyl esters in human breast subcutaneous adipose tissue 
Pre- and postmenopausal women had similar and relatively high concentrations of E2 
fatty acyl esters in breast subcutaneous adipose tissue. Compared to free E2 levels, the 
concentrations of E2 fatty acyl esters in breast subcutaneous adipose tissue were slightly 
but not significantly higher in premenopausal women. After menopause, only esterified 
E2 was quantifiable in adipose tissue. Moreover, adipose tissue total estrogen levels 
were higher than their serum levels. This is in agreement with the low hydrolysis rate of 
E2 esters, as well as the high rate of E2 esterification detectable in subcutaneous adipose 
tissue.  
The concentrations of E2 fatty acyl esters reported here were comparable with those 
measured in subcutaneous and visceral adipose tissue in women by the same TR-FIA 
method (Badeau M et al. 2007) and by others using a GC–MS method (Larner et al. 
1992). In addition, free E2 concentrations were in line with those measured by 
immunoassay (Blankenstein et al. 1992, 1999, Szymczak et al. 1998, Bolca et al. 2010), 
although most of the earlier reports concerned breast tissue obtained from breast 
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cancer patients (Blankenstein et al. 1992, 1999, Szymczak et al. 1998). In our study, 
premenopausal serum E2 concentrations analyzed by LC–MS/MS and immunoassay 
correlated well, but the concentrations of postmenopausal serum E2 as well as E2 esters 
in adipose tissue and serum were consistently lower by LC–MS/MS than by 
immunoassay. This is not unusual when comparing mass spectrometric and 
immunological methods (Lee et al. 2006). It is worth noting that, although extensive 
purification had taken place, some hydrophobic substances might still have remained 
in the E2 fatty acyl ester fraction, causing overestimation when analyzed by the 
immunologic method.  
6.4.3 E2 fatty acyl esters and gene expression of estrogen-regulating enzymes 
in obese men and women 
We found that obese men had approximately the same amount of fatty acyl esterified E2 
as nonesterified E2 in their adipose tissue, and that obese men and premenopausal 
obese women also had comparable amounts of E2 fatty acyl esters in abdominal adipose 
tissue. Although mRNA levels of steroid sulfatase and hormone-sensitive lipase genes 
were positively correlated with E2 concentration in subcutaneous fat, no significant 
correlations appeared between E2 concentrations in subcutaneous adipose tissue and 
serum. Apparently, the production of E2 by the massive adipose tissue in severely obese 
men is not reflected in circulating E2 levels. This is contrast to earlier data showing that 
serum levels of E1 were positively related to adipose tissue levels in severely obese men 
(Bélanger et al. 2006). Unlike nonesterified E2, adipose tissue levels of E2 fatty acyl 
esters correlated significantly positively with serum E2 fatty acyl ester concentrations. 
As the concentration of E2 fatty acyl esters in adipose tissue was higher than in serum, 
transfer of esterified E2 from fat tissue to serum seems possible. However, the transfer 
pathway and the mechanism behind it remains unknown.  
In contrast to men, levels of E2 in female adipose tissue were generally higher than 
their levels of E2 fatty acyl esters. This difference was more pronounced in control 
women and differs from our earlier findings that indicated comparable levels of E2 fatty 
acyl esters and E2 occurring in premenopausal female adipose tissue (Badeau M et al. 
2007). What might explain this, as discussed above, is that the current method with its 
more intensive purification steps may have led to more accurate TR-FIA analysis. 
Compared to men, women had a greater level of mRNA expression of steroid-
regulating genes and accordingly, a significantly higher concentration of E2 in 
subcutaneous adipose tissue. However, as in men, this was not reflected in serum E2 
concentration. Obese women, like men, showed a positive correlation between serum 
E2 fatty acyl ester concentrations and subcutaneous and visceral adipose tissue E2 fatty 
acyl ester levels. Despite their different fat masses, the serum concentrations of E2 fatty 
acyl esters in obese and control women were similar. 
In both genders, significantly higher mRNA levels occurred in subcutaneous fat 
than in visceral fat for hormone-sensitive lipase, steroid sulfatase, and aromatase. 
Higher expression levels have been reported of hormone-sensitive lipase and steroid 
sulfatase in subcutaneous fat versus visceral fat (Blouin et al. 2009, Ray et al. 2009). 
Whereas gene expression levels differed between the two depots of adipose tissue, the 
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concentrations of estrogen in subcutaneous fat were comparable to those in visceral 
adipose tissue. In control subjects with their weights ranging from normal to slightly 
obese, a positive correlation appeared between aromatase mRNA levels and BMI. This 
is in agreement with the findings of one earlier study (Wake et al. 2007). 
Bellemare and colleagues (2009) observed that no expression differences of 17ß-
HSD type 1, 7, and 12 appeared between subcutaneous and visceral fat in women, and 
that 17ß-HSD type 12 was involved in the conversion of E1 into E2 in differentiated 
adipocytes. This is in line with the present data, whose obese women displayed higher 
mRNA levels of 17ß-HSD type 1 in visceral fat than did control women. Conversely, 
some earlier studies found no detectable amounts of HSD17B1 mRNA in subcutaneous 
or visceral adipose tissue in women (Quinkler et al. 2004, Wang et al. 2012).  
Certain limitations in the present study are quite obvious. The study population 
consisted mainly of morbidly obese subjects undergoing bariatric surgery. Before the 
surgical operation these subjects are recommended to maintain a low-calorie diet, but 
their degree of compliance was not monitored. In addition, sudden weight loss can 
affect adipose tissue steroid metabolism. The limited size and number of fat samples 
available as well as the challenge in standardizing the tissue biopsy during surgery also 
restricted our analyses; in particular, neither protein levels nor the activities of the 
steroidigenic enzymes were measured. 
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7 SUMMARY AND CONCLUSIONS 
The major results of this thesis can be summarized as follows: 
 
        1. [3H]DHEA fatty acyl esters associated with LDL entered cultured HeLa cells via 
LDL receptors or LDL receptor-related receptors. After intracellular hydrolysis of 
[3H]DHEA fatty acyl esters, biologically active free [3H]DHEA can be converted to its 
metabolites, [3H]5?-adione and [3H]4-adione, which were secreted from the cells. LAL 
partially contributed to the hydrolysis of [3H]DHEA fatty acyl esters, a process in which 
more than one esterase species is involved.  
2. Whereas the concentrations of free DHEA in adipose tissue were 4 to 10 times as 
high as in serum, no detectable DHEA fatty acyl esters were measurable by either GC–
MS or LC–MS/MS-based methods in adipose tissue. Serum DHEA fatty acyl ester 
concentrations determined by GC–MS were 0.5 to 2.8 pmol/ml in pre- and 
postmenopausal women. The proportion of DHEA fatty acyl esters of the total DHEA in 
serum was approximately 9%.  
3. Subcutaneous adipose tissue from human breast had E2 fatty acyl esterifying and 
hydrolyzing activity. Adipose tissue contained more estrogen than did serum. The E2 
fatty acyl esters stored in adipose tissue could provide machinery for the production of 
free E2 via E2 fatty acyl ester hydrolysis, which was partly dependent on HSL.  
4. In women, concentrations of E2 in subcutaneous adipose tissue were higher than 
those in men, and this is in line with a higher expression of estrogen-regulating genes. 
However, in severely obese men or women, production of E2 by the large adipose mass 
was not reflected by an increase in the circulating E2 concentration, whereas serum E2 
fatty acyl esters correlated with adipose tissue E2 fatty acyl ester concentrations. These 
data raise the possibility that adipose tissue contributes to serum E2 fatty acyl ester 
levels possibly via transfer of E2 fatty acyl esters directly to serum from fat tissue. 
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8 CLINICAL RELEVANCE AND THE FUTURE 
These results have potential clinical relevance in two areas. First, as human adipose 
tissue contains both free hormonally active E2 and inactive E2 fatty acyl ester, as well as 
the enzymatic machineries to produce these forms, adipose tissue may in principle 
function as a source of free E2 or as a storage site for hydrophobic esterified E2. This is 
of theoretical importance in postmenopausal women whose ovarian E2 production has 
ceased and whose cardiovascular health might benefit from endogenous E2 stored in fat 
tissue. Based on our study in obese individuals, free E2 levels in adipose tissue did not 
correlate with serum E2 levels, but adipose tissue E2 fatty acyl ester levels correlated 
with those in serum. Future studies are necessary to clarify whether estrogen 
metabolites can enter the circulation from a subcutaneous fat depot. Treatment trials 
with exogenous formulations of estrogen have shown no cardiovascular benefit, 
whereas endogenous estrogen produced in the adipose tissue could, in theory, be 
cardioprotective in the same way as is ovarian estrogen before the menopause.  
Second, although free E2 might have beneficial cardiovascular effects in 
postmenopausal women, the opposite may be true in the female breast. Free E2 is 
regarded as a risk factor for breast cancer. As both esterifying and de-esterifying 
enzymatic activities are present in adipose tissue, the balance between these two 
pathways is important. Locally dominant E2 esterification activity could be beneficial by 
inactivating E2, but dominant de-esterification could result in high local E2 
concentrations which might enhance carcinogenesis. In theory, activation of E2 
esterification or inhibition of E2 fatty acyl ester hydrolysis could reduce the risk of 
breast cancer. Future studies are crucial to test these hypotheses and to investigate 
whether this system has therapeutical value. 
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